Document:

EX-10.13

                      LIVESTOCK DATABASE LICENSE AGREEMENT

This LIVESTOCK DATABASE LICENSE AGREEMENT ("Agreement") is entered into as of
this 28TH day of February, 2002 (the "Effective Date") by and between PE
CORPORATION (NY), a New York corporation, through the Celera Genomics Group
("Celera"), having a place of business at 45 West Gude Drive, Rockville,
Maryland 20850 and METAMORPHIX, INC., a Delaware corporation ("MMI"), having a
principal place of business at 1450 South Rolling Road, Baltimore, Maryland
21227.

        WHEREAS, Celera has an online information system to organize, analyze
and deliver medically relevant biological information for research and discovery
and a marketing and sales infrastructure to promote and license biological
information; and

        WHEREAS, Celera has expended and will continue to expend significant
resources and efforts to develop a variety of genomic databases, related
biological information and analysis resources;

        WHEREAS, Celera has sequenced and assembled bovine, porcine and poultry
genome sequence and identified certain SNPs for these genomes;

        WHEREAS, MMI desires, subject to the terms and conditions of this
Agreement, to obtain access to certain genomic databases, and the right to use
certain software tools for the analysis of such databases;

        WHEREAS, Celera is willing, subject to the terms and conditions of this
Agreement, to grant MMI access to such databases and the right to use such
tools.

NOW THEREFORE, the Parties agree as follows:

                                    ARTICLE 1

                                   DEFINITIONS

        1.1     "AAA" shall mean the American Arbitration Association.

        1.2     "Affiliate" shall mean any corporation, firm, partnership or
other legal entity that, directly or indirectly, controls, is controlled by, or
is under common control with MMI but shall not include any such corporation,
firm, partnership or other legal entity that provides genomic products and
services substantially similar to Celera. A corporation or other entity shall be
regarded as in control of another corporation or entity, if (a) in the case of
corporate entities it owns or directly or indirectly controls more than fifty
percent (50%) of the outstanding voting stock or other ownership interest of the
other corporation or entity, or if it possesses, directly or indirectly, the
power to manage, direct or cause the direction of the management and policies of
the corporation or other entity or the power to elect or appoint fifty percent
(50%) or more of the members of the governing body of the corporation or other
entity, and (b) in the case of non-corporate

                                       1
<PAGE>

entities, direct or indirect ownership of at least fifty percent (50%) interest
with the power to direct the management and policies of such non-corporate
entities.

        1.3     "Agreement Products and Technology" shall mean the BPP Products
and Technology and BPP SNP Map and Technology.

        1.4     "Agricultural Product(s) and Service(s)" shall mean any Product
or service to improve livestock and aquaculture production. When the context is
appropriate, reference may also be made solely to Agricultural Products(s) or to
Agricultural Services(s).

        1.5     "Association Study" shall mean a series of experiments employing
genotyping and bioinformatics to the association of known SNPs with certain
phenotypes expressed in DNA samples.

        1.6     "Authorized Use" shall have the meaning set forth in Section
2.6.

        1.7     "Bovine Product" shall mean the database product set forth in
items la. and 2 of Schedule 1.9.

        1.8     "Bovine Royalty Payment" shall have the meaning set forth in
Section 6.1(b).

        1.9     "BPP Products and Technology" shall mean the Bovine Product,
Porcine Product and Poultry Product, together with the Tools described in
Schedule 1.9, and any Celera documentation for such products.

        1.10    "BPP Subscription" shall mean MMI's subscription to the BPP
Products and Technology.

        1.11    "BPP SNP Map and Technology" shall mean the SNP Maps and Tools
listed and described in Schedule 1.9, and any documentation for such products.

        1.12    "BPP SNP Map Subscription" shall mean MMI's subscription to the
BPP SNP Map and Technology.

        1.13    "Celera Technology" shall mean (a) all data, information,
inventions, know-how, technology, trade secrets and the like, including, but not
limited to, nucleotide sequences, whether as genomic DNA, cDNA, synthetic DNA,
RNA or the like, ribozymes containing any of the foregoing, vectors containing
any of the foregoing, gene therapy delivery systems or control systems
containing any of the foregoing, host cells containing any of the foregoing,
amino acid sequences encoded by any of the foregoing, antibodies, and processes
and uses of any of the foregoing (and any related information, including, but
not limited to allele frequency, haplotypes and processes and uses of any of the
foregoing), whether patentable or not, and (b) that are conceived of, developed,
discovered, identified or invented in whole or in part by Celera independent of
MMI.

        1.14    "Confidential Information" shall mean (a) the terms of this
Agreement, and (b) all non-public business information, trade secrets and
technical information

                                       2
<PAGE>

relating to Celera Technology, MMI Technology or other information, including,
but not limited to all data, information, inventions, know-how, technology,
trade secrets and the like belonging to the Disclosing Party, including, where
appropriate and without limitation, any associated information, business,
financial and scientific data, DNA Sequence Information, invention disclosures,
patent disclosures, patent applications (and related files and strategies),
structures, models, techniques, processes, compositions, compounds, biological
samples, and the like, and bioinformatics methods, hardware configurations and
software in various stages of development or any software product (source code,
object code or otherwise), including its audiovisual components (menus, screens,
structure and organization) and any human or machine readable form of the
program, and any writing or medium in which the program or information therein
is stored, written or described, including, without limitation, diagrams, flow
charts, designs, drawings, specifications, models, data, bug reports, and the
like.

        1.15    "Confidentiality Agreement" shall mean the Confidentiality and
Nondisclosures Agreement between MMI and Celera, effective November 20, 2000.

        1.16    "Default" shall mean a Performance Default and/or Representation
Default

        1.17    "Disclosing Party" shall have the meaning set forth in Section
7.1(a).

        1.18    "DNA Sequence Information" shall mean the respective consensus,
non-redundant bovine, porcine, and poultry nucleotide sequences from nucleotide
templates sequenced through Celera's internal sequencing programs and released
to MMI.

        1.19    "Economic Consideration" shall mean revenue derived from any MMI
agreement for the development, marketing, sale or distribution of Agricultural
Product to Third Parties including without limitation, research and development
payments, payments in the form of equity in a Third Party, payments for equity
in MMI (to the extent such payments exceed the value of such MMI equity),
license fees, maintenance fees, milestones, and royalties.

        1.20    "Effective Date" shall have the meaning set forth in the first
paragraph of this Agreement.

        1.21    "Existing Senior Securities" shall have the meaning set forth in
the Certificate of Designations of the Series E Convertible Preferred Stock of
MMI.

        1.22    "Foundation Customer" shall have the meaning set forth in
Section 2.5(b).

        1.23    "Indemnitee" shall mean the Party that intends to claim
indemnification under Article 12 of this Agreement.

        1.24    "Indemnitor" shall mean the Party from which the Indemnitee
seeks indemnification.

                                       3
<PAGE>

        1.25    "MMI Contractor(s)" shall mean any Third Party with whom MMI has
contracted to pursue and/or complete, solely on MMI's behalf, MMI's research
and/or development activities. MMI Contractor(s) shall be subject to an
agreement with MMI for the confidential treatment of information exchanged in
substantial conformity to the confidentiality provisions of this Agreement, and
shall not retain any right, title and/or interest in or to any property rights
resulting from such MMI research and/or development activities and all such
rights shall reside solely in MMI.

        1.26    "MMI Site" shall mean one of MMI's facilities or places of
business that MMI identifies to Celera and Celera authorizes to receive
information that MMI accesses from Celera hereunder.

        1.27    "MMI Technology" shall mean all data, information, inventions,
know-how, technology, trade secrets and the like including, but not limited to,
nucleotide sequences, whether as genomic DNA, cDNA, synthetic DNA, RNA or the
like, ribozymes containing any of the foregoing, vectors containing any of the
foregoing, gene therapy delivery systems or control systems containing any of
the foregoing, host cells containing any of the foregoing, amino acid sequences
encoded by any of the foregoing, antibodies, and processes and uses of any of
the foregoing, whether patentable or not, that are conceived of, developed,
discovered, identified or invented, during or after the Term, in whole or in
part, by MMI as a direct result of MMI's Authorized Use of the Agreement
Products and Technology and independent of Celera.

        1.28    "Party" shall mean either Celera or MMI; "Parties" shall mean
both Celera and MMI.

        1.29    "Performance Default" shall mean a breach or default of a
material obligation of this Agreement.

        1.30    "Poultry Product" shall mean the database product set forth in
items lc. and 2 of Schedule 1.9.

        1.31    "Porcine Product" shall mean the database product set forth in
items lb. and 2 of Schedule 1.9.

        1.32    "Product(s)" shall mean any (a) article or substance consisting
of, derived from, or designed to interact with DNA Sequence Information or (b)
and technology, method, know how or service derived from DNA Sequence
Information.

        1.33    "Receiving Party" shall have the meaning set forth in Section
7.1(a).

        1.34    "Records" shall mean MMI's documentation of its access to and
use of the DNA Sequence Information.

        1.35    "Regulatory Approval" shall mean, with respect to the US,
European Union or Japan, the first approval or clearance by any national,
supra-national, regional, state or local regulatory agency, department, bureau,
commission, council or other

                                       4
<PAGE>

governmental entity, permitting the lawful manufacture, distribution, use,
import, export or sale of a Product in such country or geographic region.

        1.36    "Representation Default" shall mean the untruth of any material
representation or warranty given hereunder by a Party.

        1.37    "Series E Convertible Preferred Stock" means MMI's Series E
Convertible Preferred Stock.

        1.38    "Series E Preferred Stock Purchase Agreement" shall mean the
agreement of such title between the Parties.

        1.39    "Third Party" shall mean any individual, partnership, joint
venture, corporation, trust, estate, unincorporated organization, government or
any department or agency thereof, or other entity other than MMI or Celera.

        1.40    "Tools" shall mean the algorithms and software as set forth on
Schedule 1.9.

                                    ARTICLE 2

                               LICENSE AND OPTION

        2.1     License to BPP Products and Technology. Subject to the terms and
conditions of this Agreement, Celera hereby grants to MMI, a non-exclusive,
perpetual, worldwide license (with no right to sublicense), to access and use
the BPP Products and Technology solely within the Authorized Use.

        2.2     License to BPP SNP Map and Technology. Subject to the terms and
conditions of this Agreement, Celera hereby grants to MMI, a non-exclusive,
perpetual, worldwide license (with no right to sublicense), to access and use
the BPP SNP Map and Technology. solely within the Authorized Use.

        2.3     Option for Exclusivity. Celera hereby grants MMI an exclusive
option to convert the non-exclusive license granted pursuant to Section 2.1 into
an exclusive, perpetual license, and convert the non-exclusive license granted
pursuant to Section 2.2 into an exclusive, perpetual license (together, the
"Option"); provided however, that any and all rights to use the Tools set forth
in the Schedule 1.9 shall remain non-exclusive for all purposes; and provided
further that MMI meets each of the following conditions during the Option Period
(defined below):

                (a)     MMI pays Celera two million dollars ($2,000,000)
pursuant to Section 4.1(b); and

                (b)     After the Effective Date, either (a)

                                       5
<PAGE>

                        (i)     MMI raises gross cash proceeds of at least
fifteen million dollars ($15,000,000) through one or more equity financings from
research and development payments, and/or by other means; or

                        (ii)    On a product-by-product basis, MMI enrolls two
(2) Foundation Customers pursuant to Section 2.5(b); provided however, if MMI
has satisfied the condition set forth in Section 2.3(a), and MMI enrolls a
Foundation Customer for one (1) but not two (2) of the species for the databases
that comprise the BPP Products and Technology (the Bovine Product, Porcine
Product and Poultry Product), then MMI's exclusivity granted pursuant to
satisfying this subsection 2.3(c)(ii) shall be limited to the product for which
such single Foundation Customer is enrolled.

        For clarification, the achievement of exclusivity provided in this
Section 2.3 in no way excuses MMI's obligation to make the payment pursuant to
Section 4.1(b). Furthermore, if MMI makes the payment pursuant to Section 4.1(b)
and enrolls two (2) Foundation Customers, then, subject to Section 2.5(b), the
non-exclusive license granted pursuant to Section 2.1 shall be exclusive for all
three (3) species.

        2.4     Exercise of the Option. Subject to the conditions specified in
Section 2.3, MMI may exercise the Option at any time during the period beginning
on the Effective Date and ending six (6) months thereafter (the "Option Period")
by giving Celera written notice together with reasonable written documentary
proof of MMI's fulfillment of the conditions specified in Section 2.3. During
the Option Period, Celera will not grant a license or an option to take a
license to the BPP Products and Technology or BPP SNP Map and Technology to any
Third Party within the Authorized Use. Notwithstanding anything to the contrary
herein, MMI's failure to satisfy the conditions to the Option specified in
Section 2.3, or MMI's failure to exercise the Option for any other reason, shall
not affect in any manner, any of MMI's obligations specified herein, including
without limitation, the obligations cross referenced in Section 2.3.

        2.5     Scope and Conditions of Exclusivity. The exclusivity granted
pursuant to the Option may terminate as provided in this Section 2.5.
Notwithstanding MMI's exercise of the Option, the exclusive licenses granted
pursuant to the Option will become nonexclusive on the earlier to occur of the
following without notice if prior to a date which is thirty (30) months after
the Effective Date, one (1) of the following conditions has not been met:

                (a)     Celera has received revenue sharing and royalties (as
set forth in Article 6) from MMI totaling at least two (2) million dollars
($2,000,000); provided MMI may make up any shortfall, up to twenty percent (20%)
of such amount, by making a one time, nonrefundable non-creditable cash payment
to Celera prior to such date; or

                (b)     MMI has enrolled a Foundation Customer for two (2) of
the databases, or two (2) Foundation Customers each for one (1) of the
databases, that comprise the BPP Products and Technology (the Bovine Product,
Porcine Product and Poultry Product). Notwithstanding the preceding sentence,
the condition of this Section 2.5(b)will be satisfied in the event MMI enrolls
any number of customers that taken together would

                                       6
<PAGE>

satisfy the condition in the preceding sentence even if individually such
customers would not satisfy the condition. For purposes of this Agreement, a
"Foundation Customer" means a customer contractually obligated to pay one
hundred percent (100%) of the costs of the validation and first Association
Study for the relevant SNP Map. For clarification, a single corporation may be a
Foundation Customer for any number of the databases, that comprise the BPP
Products and Technology; provided however, in the event that MMI, in accordance
with this Section 2.5(b), enrolls a Foundation Customer for one (1) but not two
(2) of the databases, then MMI's exclusivity solely with respect to the BPP
Products and Technology and BPP SNP Maps for the species for such one (1)
database would continue in accordance with the other terms of this Section 2.5.

        2.6     Authorized Use.

                (a)     MMI's right to access and use the Agreement Products and
Technology through the BPP Subscription and BPP SNP Map Subscription are
exercisable through the methods authorized herein for the purpose of conducting
MMI's research and development solely in the interest of and on behalf of MMI
and solely for the development and commercialization of Agricultural Products
and Services.

                (b)     MMI shall not reproduce, adapt, prepare derivative works
based upon, or distribute copies of any portion of the BPP Subscription, BPP SNP
Map Subscription and/or Agreement Products and Technology for any purpose.
Additionally, MMI shall not rent or loan the BPP Subscription or BPP SNP Map
Subscription or reverse engineer, decompile, disassemble or otherwise attempt to
access any source code for any software program included in the BPP Subscription
or BPP SNP Map Subscription (except to the extent permitted by Schedule 1.9).
MMI further shall use reasonable efforts to prevent any unauthorized copying,
distribution, reverse engineering, decompiling, and disassembling of any of the
Agreement Products and Technology through appropriate methods, including, but
not limited to, agreements entered into by MMI with its employees, consultants,
contractors and collaborators. MMI shall have the right to access the BPP
Subscription and BPP SNP Map Subscription by the method authorized in Section
3.1 for two (2) pre-designated sites located in Davis, California (or its
successor facility) and Baltimore, Maryland (or its successor facility) for
internal re-distribution to other MMI Sites designated in writing to Celera as
of the Effective Date or consented to in writing by Celera after the Effective
Date, which consent shall not be unreasonably withheld or delayed.

                (c)     The foregoing provisions of this Section 2.6 shall be
collectively defined as "Authorized Use".

                (d)     For clarification, nothing in this Agreement will be
construed to limit in any way the use or transfer of Agreement Products and
Technology by Celera at any time for any purpose outside the Authorized Use,
including without limitation, the development and commercialization of any
product alone or with any Third Party for the prevention, treatment or diagnosis
of any disease or condition in humans.

                                       7
<PAGE>

                                    ARTICLE 3

                         SUBSCRIPTION ACCESS AND RECORDS

        3.1     MMI BPP Subscription and BPP SNP Map Subscription Access.
According to the terms of this Agreement and not later than forty-five (45) days
after the Effective Date, Celera shall provide MMI with access to the Agreement
Products and Technology under the BPP Subscription and BPP SNP Map Subscription
through the methods specified in Schedule 1.9.

        3.2     Celera will provide necessary and appropriate training to MMI
for the use of the Tools.

        3.3     In the event Celera provides updates, upgrades or improvements
to the Tools to Celera's similarly situated customers, Celera will use
commercially reasonable efforts to provide such updates, upgrades or
improvements to MMI on Celera's then current terms and conditions.

        3.4     Records.

                (a)     MMI shall maintain Records sufficient to enable MMI and
Celera to monitor compliance with and enforce their respective rights and
obligations under this Agreement, including without limitation, payments
receivable pursuant to Article 6 and laboratory notebooks and such other records
as are customary for documenting research and product development activities.

                (b)     No more than once a year, unless as otherwise agreed in
writing, upon Celera's request and at its expense, MMI shall permit an
independent agent.appointed by Celera and acceptable to MMI (such acceptance not
to be unreasonably withheld or delayed) to examine MMI's Records solely to the
extent necessary to verify the fulfillment of MMI's obligations under this
Agreement; provided, however, that Celera and such agent have entered into a
confidentiality agreement that contains confidentiality provisions substantially
similar to the terms of this Agreement (including provisions of non-use and
non-disclosure). Celera's agent shall report to Celera only the results of such
examination (i.e., whether or not MMI is in compliance with its obligations
under this Agreement together with the amounts of any overpayment or under
payment), and shall not disclose to Celera or any Third Party any of MMI's
Confidential Information provided to it or to which it may have had access
during the conduct of the examination. Thereafter, within thirty (30) days MMI
shall pay Celera or Celera shall pay MMI any overpayment or under payment as
applicable.

                                    ARTICLE 4

                                    PAYMENTS

        4.1     Agreement Products and Technology Fees

                (a)     Concurrently with the execution and delivery of this
Agreement, MMI is issuing an aggregate of two million (2,000,000) shares of the
MMI's Series E Convertible Preferred Stock, par value $0.001 per share, to
Celera for a purchase price of

                                       8
<PAGE>

$17.50 per share pursuant to, and under the terms and conditions set forth in,
the Series E Preferred Stock Purchase Agreement, 1.714 million of which shares
are being issued to Celera in consideration of the licenses granted hereunder;
and

                (b)     MMI will pay Celera two million dollars ($2,000,000)
within twelve (12) months of delivery to MMI of the completed SNP maps.

        4.2     Taxes. All amounts payable under this Agreement are exclusive of
all sales, use, value-added, withholding, and other taxes and duties. MMI will
pay all taxes and duties assessed in connection with this Agreement and its
performance by any authority within or outside of the U.S., except for taxes
payable on Celera's net income and those taxes by law imposed upon Celera.

        4.3     Failure by MMI to Make Timely Payment.

                (a)     Notice and Right to Terminate. In the event Celera has
not received any cash payment due under this Agreement by the prescribed due
date, Celera shall notify MMI of such non-payment. In the event that Celera has
not received payment within thirty (30) days after receipt by MMI of such notice
from Celera, Celera shall have the right to suspend MMI's access to the BPP
Subscription and/or BPP SNP Map Subscription in addition to any other remedies
that may be available to Celera at law or in equity until MMI makes such
payment. In the event that such payment is not made within ninety (90) days of
MMI's receipt of such notice, Celera shall have the additional right to
terminate this Agreement.

                (b)     Late Payment. Any payment due under this Agreement that
is not paid on or before the date such payment is due shall bear interest to the
extent permitted by applicable law, at one percentage point (1%) over the prime
rate of interest compounded on an annual basis as reported by Bank of America
NT&SA in San Francisco, California, from time to time, calculated on the number
of days such payment is delinquent.

                (c)     Mode of Payments. All payments under this Agreement will
be nonrefundable and paid in U.S. Dollars by deposit to the credit and account
of Celera by mail or by wire as Celera will designate from time to time.

                                    ARTICLE 5

              RIGHT OF FIRST OFFER TO GENOME AND SNP MAP SEQUENCING

Celera hereby grants MMI a right of first offer to negotiate rights to Celera's
services for genome and SNP map production for food-producing animals other than
bovine, porcine, and poultry, and companion animals, solely for the development
and commercialization of Agricultural Products and Services (the "Services"). If
Celera intends to offer the Services to any Third Party, Celera will not
negotiate or offer to negotiate an agreement to provide the Services without
first offering in writing to conduct such Services for MMI. Thereafter, MMI will
have the option, but not the obligation, to negotiate the terms and conditions
of an agreement to provide the Services whereupon MMI and Celera will negotiate
in good faith. If MMI declines to exercise the option in writing or

                                       9
<PAGE>

the Parties fail to execute an agreement within sixty (60) days of Celera's
written notice of the option to MMI, then Celera will be free to offer the
Services to any Third Party, provided that any terms offered to such Third
Party, considered as a whole, are not materially more favorable than those terms
last offered to MMI. MMI, on its own initiative, may request that Celera
contract to provide such Services, whereupon Celera shall negotiate in good
faith and offer an agreement consistent with the terms and conditions of like
agreements then offered by Celera. MMI will exercise the option, if at all,
prior to December 31, 2003, by written response to any notice of offer from
Celera or upon written notice by MMI for MMI's desire to contract for such
Services.

                                    ARTICLE 6

                          REVENUE SHARING AND ROYALTIES

        6.1     MMI will pay Celera from revenue received by MMI in accordance
with the following schedule:

                (a)     Twenty percent (20%) of all Economic Consideration
derived by MMI from any contract, agreement or other business relationship
utilizing the BPP Products and Technology and/or BPP SNP Maps and Technology for
porcine and poultry, provided such contract, agreement or other business
relationship is entered into during the four (4) years following the Effective
Date. Such amounts will be payable net thirty (30) days following receipt of
Economic Consideration; provided however, following MMI's initial public
offering, such payments shall be made thirty (30) days following the end of the
quarter within which MMI received such Economic Consideration.

                (b)     Three percent (3%) of all Economic Consideration derived
by MMI for fifteen (15) years following the Effective Date from any contract,
agreement or business relationship utilizing the BPP Products and Technology or
BPP SNP Map and Technology for bovine (the "Bovine Royalty Payment"). Such
amounts will be payable net thirty (30) days following receipt of Economic
Consideration; provided however, following MMI's initial public offering, such
payments shall be made thirty (30) days following the end of the quarter within
which MMI received such Economic Consideration.

        6.2     MMI Annual Payment: On each anniversary of the Effective Date,
MMI will pay Celera five hundred thousand dollars ($500,000) minus the Bovine
Royalty Payment for the preceding year (adjusted for any credits) provided the
Bovine Royalty Payment for the preceding year (adjusted for any credits) is less
than five hundred thousand dollars ($500,000) (the "MMI Annual Payment"). Any
MMI Annual Payment shall be fully creditable against any future Bovine Royalty
Payment. If the Bovine Royalty Payment for the preceding year (adjusted for any
credits) is equal to or greater than five hundred thousand dollars ($500,000),
the MMI Annual Payment will be waived. Such Annual Payment obligation will
continue for 15 years. For clarification, for each year for fifteen years, if
the Bovine Royalty Payment owed for such year is greater than five hundred
thousand dollars ($500,000), MMI will pay Celera such Bovine Royalty Payment
(adjusted for any credits), and if the Bovine Royalty Payment owed for such year
is less

                                       10
<PAGE>

than five hundred thousand dollars ($500,000), MMI will pay Celera five hundred
thousand dollars ($500,000), and any amount by which such five hundred thousand
dollars ($500,000) exceeds the Bovine Royalty Payment owed for such year shall
be fully creditable against any future Bovine Royalty Payment.

        6.3     In the event MMI receives any consideration in excess, in the
aggregate, of one million dollars ($1,000,000) from any Foundation Customer with
regard to any combination of contracts, agreements or other business
relationships utilizing the Porcine Product (a "Porcine Deal"), MMI will pay
Celera one million dollars ($1,000,000), net thirty (30) days from the date MMI
receives such aggregate amount; provided however, if the date MMI first receives
any consideration with regard to the first Porcine Deal (the "Payment Date")
falls during the Option Period or following the date MMI exercises the Option
for such Porcine Product pursuant to Section 2.3, such one million dollars
($1,000,000) shall be payable to Celera net thirty (30) days from the Payment
Date, regardless of the aggregate amount received by MMI pursuant to such
Porcine Deal. Furthermore, provided such payment is received by Celera, a total
of one million dollars ($1,000,000) of consideration received by MMI for any
Porcine Deal shall be exempt from the calculation of Economic Consideration for
purposes of Section 6.1(a).

        6.4     In the event MMI fails to exercise the Option during the Option
Period or the exclusivity granted pursuant to the Option terminates pursuant to
Section 2.5, and thereafter, Celera enters an agreement of similar scope in
direct competition with MMI for less consideration with a similarly situated
Third Party, then MMI may within thirty (30) days of notice of such agreement
elect to substitute the provisions providing consideration to Celera under such
agreement for the consideration provisions of this Agreement; provided however,
that (i) any consideration paid to Celera or payable hereunder prior to such
election by MMI shall be non-refundable and non-creditable, and (ii) MMI adopts
all of the additional restrictions, obligations and license limitations imposed
in such agreement. Celera will provide MMI, within thirty (30) days after the
close of any such agreement that Celera reasonably determines to be more
favorable, with the material terms of each such agreement. In determining
whether an agreement is of a similar scope and the consideration is less, all
the terms of this Agreement and such agreement shall be analyzed as a whole.

                                    ARTICLE 7

                         CONFIDENTIALITY AND PUBLICATION

        7.1     Confidentiality. The Parties acknowledge that the
Confidentiality Agreement controls and shall continue to control all disclosures
from the effective date of such agreement up to and until the Effective Date.
The Parties agree that the Confidentiality Agreement is hereby superseded by the
terms and conditions set forth in this Article 7 and the other applicable terms
and conditions set forth in this Agreement. All information and documentation
deemed to be "Confidential Information" under the superseded Confidentiality
Agreement will be deemed to be Confidential Information under Section 1.14 and
this Article 7.

                                       11
<PAGE>

                (a)     The Parties acknowledge that during the course of this
Agreement they may each receive (and hence become a "Receiving Party") from the
other (the "Disclosing Party") information electronically, in writing or orally,
that is proprietary and/or confidential and of commercial value to the
Disclosing Party. The Parties agree that they shall take all reasonable measures
to protect the secrecy of and avoid disclosure and unauthorized use of the
Confidential Information. Without limiting the foregoing, the Parties shall take
at least those measures that each takes to protect its own confidential
information of a similar nature, but in no event less than a reasonable degree
of care. Both Parties shall immediately notify the other in the event that
either Party has knowledge of any unauthorized use or disclosure of the
Confidential Information.

                (b)     Except to the extent expressly authorized by this
Agreement, the Parties agree that the Receiving Party shall keep confidential
and shall not publish or otherwise disclose, and shall not use for any purpose,
any Confidential Information furnished to it by the Disclosing Party pursuant to
this Agreement, regardless of the medium on which it is provided, including
know-how, except to the extent that it can be established by the Receiving Party
by competent proof that such information:

                        (i)     was already known to the Receiving Party, other
than under an. obligation of confidentiality, at the time of disclosure by the
Disclosing Party;

                        (ii)    was generally known to the public or otherwise
part of the public domain at the time of its disclosure to the Receiving Party;

                        (iii)   became generally available to the public or
otherwise part of the public domain after its disclosure through no action or
inaction of the Receiving Party;

                        (iv)    was subsequently lawfully disclosed to the
Receiving Party by a Third Party who did not require the Receiving Party to hold
it in confidence or limit its use, provided it was not obtained by such Third
Party under an obligation of confidentiality directly or indirectly from the
Disclosing Party; or

                        (v)     was independently discovered or developed by the
Receiving Party without the use of or access to the Disclosing Party's
Confidential Information, as can be documented by written records created at the
time of such independent discovery or development.

                (c)     No MMI Confidential Information shall appear on (i) any
public Celera database or (ii) any Celera database that Celera shares with any
Third Party or uses for internal Celera research and development.

        7.2     Permitted Disclosure.

                (a)     Subject to Article 2 and Article 8, MMI may disclose
specific, as needed, DNA Sequence Information (including without limitation,
individual SNPs) only to the extent such disclosure is required for filing or
prosecuting a patent application and maintaining a patent, Regulatory Approval,
to bona fide potential investors, customers,

                                       12
<PAGE>

Foundation Customers, each of the foregoing subject to an agreement with MMI for
the confidential treatment of information exchanged in substantial conformity to
the confidentiality provisions of this Agreement.

                (b)     Notwithstanding the obligations of Section 7.1, the
Receiving Party may disclose the Disclosing Party's Confidential Information in
establishing rights or enforcing obligations under this Agreement, or complying
with applicable law; provided however, that in each case described herein if a
Receiving Party shall be required to make any disclosure of the Disclosing
Party's Confidential Information under this Section 7.2(b), it will (i) give
reasonable advance notice to the Disclosing Party of such disclosure
requirement; (ii) provide a copy of the proposed disclosure; and (iii) use
commercially reasonable efforts in assisting the Disclosing Party to secure
confidential treatment of such Confidential Information required to be
disclosed, including cooperating with the other to obtain a protective order for
the Disclosing Party's Confidential Information.

                (c)     MMI may disclose DNA Sequence Information only in the
context of the disclosure of MMI's own scientific results and then only to those
MMI Contractors and MMI's employees and consultants who (a) have a need-to-know,
and (b) are under contract not to disclose or use Confidential Information,
except as otherwise provided herein.

        7.3     Copies. Unless otherwise previously approved in writing by the
Disclosing Party, a Receiving Party shall not make any copies of the Disclosing
Party's Confidential Information except as permitted under Section 7.2 or, in
the case of MMI and MMI Contractors, as reasonably necessary for MMI's internal
research and development as authorized in Section 2.6.

        7.4     Publication. MMI may publish scientific results of its work
within the scope of the license granted under this Agreement, provided however,
that:

                (a)     at least thirty (30) days prior to submission for
publication of any document, slides, lecture, and/or any other method or form of
publishing that would disclose Celera's Confidential Information not disclosable
under Section 7.2, MMI shall submit a copy of such publication to Celera for
Celera's prior review, comment and written consent, such consent not to be
unreasonably withheld or delayed. Celera, at its discretion, may remove the
Confidential Information or approve such disclosure of Confidential Information;
provided, however, that in no event shall Celera delay any such planned
publication beyond such thirty (30) day period. If Celera has not removed the
Confidential Information and/or responded to MMI's request for approval within
thirty (30) days of MMI' s submission to Celera, such planned publication shall
be deemed approved by Celera. MMI agrees that Celera may keep a copy of such
publication for its records. MMI further agrees that upon receiving notification
by the publisher of the intent to release a publication, MMI shall advise Celera
of such publication, the planned publication date, and furnish a final copy of
the publication; and

                                       13
<PAGE>

                (b)     any such publications shall include recognition of the
contributions of Celera according to standard practice for assigning scientific
credit, either through authorship or acknowledgement as may be appropriate.

        7.5     Restricted Use. Except as otherwise expressly set forth in this
Agreement, this Article 7 shall not be construed to allow MMI, MMI Contractors,
MMI's employees and consultants or any other person or entity to access, use,
publish, disclose, re-package or re-distribute the Agreement Products and
Technology or any portion of their contents, including, but not limited to, any
DNA Sequence Information any source code or object code, or any Celera software
or hardware configurations, at any time without the express written consent of
Celera.

        7.6     Equitable Relief. Each Party acknowledges and agrees that with
respect to the nature of the Confidential Information, there may be no adequate
remedy at law for any breach of the a Party's obligations under the
confidentiality provisions of this Agreement, that any such breach may result in
irreparable harm to the other Party, and therefore, that upon any such breach
the other Party shall be entitled to seek equitable relief, in addition to
whatever remedies it might have at law, including injunctive relief, specific
performance or such other relief as such other Party may request to enjoin or
otherwise restrain any act prohibited hereby, as well as the recovery of all
costs and expenses, including reasonable attorneys' fees.

                                    ARTICLE 8

                              INTELLECTUAL PROPERTY

        8.1     Celera Rights. Subject to the rights granted hereunder, Celera
retains all rights, title and interest to and in the Agreement Products and
Technology within the BPP Subscription and BPP SNP Map Subscription and to all
Celera Technology. To avoid doubt, with the exception of the rights expressly
granted under this Agreement, MMI, its Affiliates, MMI Contractors, and MMI
employees shall have no rights, claims or interests whatsoever (including, but
not limited to, any intellectual property rights) with respect to the Agreement
Products and Technology within the BPP Subscription or BPP SNP Map Subscription,
Celera Technology, patents or patent applications containing Celera Technology
or products incorporating Celera Technology.

        8.2     MMI Rights and Obligations. As between the Parties, MMI shall
own all rights, title and interest in and to MMI Technology. MMI shall be
permitted to transfer MMI Technology as follows:

                (a)     Patent and Development Costs. If MMI elects to pursue
patent applications for or covering MMI Technology, including any Product, MMI
shall assume responsibility for all costs associated with the application,
prosecution and maintenance, and the defense and enforcement of patent
applications and patents claiming any such MMI Technology. MMI shall assume
responsibility for all costs associated with a Regulatory Approval.
Contemporaneous with the publication of a patent or patent

                                       14
<PAGE>

application or a Regulatory Approval that discloses a nucleotide sequence within
DNA Sequence Information, MMI shall provide Celera with a copy of such
publication.

                (b)     Nothing in this Agreement is intended or shall be
interpreted as granting to MMI or any Third Party any right or interest in any
intellectual property (a) invented, discovered, developed, or otherwise created
by PE Corporation (NY), or its Affiliates, other than by the Celera Genomics
Group, or (b) acquired or licensed by PE Corporation (NY), or its Affiliates,
other than solely for the benefit of the Celera Genomics Group.

        8.3     Third-Party Infringement. If Celera believes that the data,
information or software within the BPP Subscription or any part thereof,
infringes any patent, copyright, trademark, or other proprietary right, or if
the licensing or use of the BPP Subscription or any part thereof, is, as a
result, enjoined, then Celera may, at its election, option, and expense: (a)
procure for MMI the right under such proprietary right to use such data,
information or software or such part thereof; or (b) replace such data,
information or software, or such part thereof, with other non-infringing data,
information or software or parts having substantially the same purpose; or (c)
suitably modify the data, information or software, or part thereof, to become
non-infringing; or (d) if unable to accomplish' (a), (b), or (c) after using
commercially reasonable efforts to do so, remove the infringing data,
information or software, or part thereof, and make an equitable adjustment of
the fees paid hereunder, including a refund thereof, as mutually agreed upon.

                                    ARTICLE 9

                              TERM AND TERMINATION

        9.1     Term. Unless terminated earlier as provided herein, this
Agreement shall commence on the Effective Date and shall remain in full force
for the duration of any payment obligations of MMI hereunder.

        9.2     Default.

                (a)     Notice of Default. In the event of a Representation
Default or Performance Default by either Party, the non-defaulting party must
first give the defaulting party written notice thereof, which notice must state
the nature of the falsehood, breach or default in reasonable detail and request
the defaulting party cure such Default within ninety (90) days, except as
otherwise provided herein. Such notice must be addressed to the person(s) and/or
office(s) identified in Section 13.10.

        9.3     Termination for Default. The non-defaulting party may terminate,
in addition to any other remedies that may be available to such non-defaulting
party at law or in equity, this Agreement in the event of (a) a Representation
Default by the defaulting party, or (b) a Performance Default by the defaulting
party; if such Default that has not been cured within the one hundred twenty
(120) day period, or such other period provided herein, after receipt of the
written notice of termination from the non-defaulting party. Nevertheless if
such Performance Default cannot be cured within such period, and the defaulting
party shall have failed to commence substantial remedial actions within

                                       15
<PAGE>

such period and to diligently pursue the same. Notwithstanding the foregoing, if
a Representation or Performance Default is not curable by its nature, the
non-defaulting party may terminate this Agreement, which termination shall be
effective on the tenth day following written notice to the defaulting party.

        9.4     Bankruptcy.

                (a)     A Party may terminate this Agreement if, during the
Term, the other Party shall file in court or agency pursuant to any statute or
regulation of any state or country, a petition in bankruptcy or insolvency or
for reorganization or for an arrangement or for the appointment of a receiver or
trustee of the Party or of its assets, or if the other Party proposes a written
agreement of composition or extension of its debts, or if the other Party shall
be served with an involuntary petition in bankruptcy or seeking reorganization,
liquidation, dissolution, winding-up arrangement, composition or readjustment of
its debts or any other relief under any bankruptcy, insolvency, reorganization
or other similar act or law of any jurisdiction now or hereafter in effect, or
there shall have been issued a warrant of attachment, execution, distraint or
similar process against it, filed in any insolvency proceeding, and such
petition shall not be dismissed within ninety (90) days after the filing
thereof, or if the other Party shall propose or be a Party to any dissolution or
liquidation, or if the other Party shall make an assignment for the benefit of
creditors.

                (b)     All rights and licenses granted under or pursuant to
this Agreement are, and shall otherwise be deemed to be, for purposes of Section
365(n) of the U.S. Bankruptcy Code, licenses of rights to "intellectual
property" as defined under Section 101 of the U.S. Bankruptcy Code. The Parties
agree that MMI is a licensee of such rights under this Agreement and shall
retain and may fully exercise all of its rights and elections under the U.S.
Bankruptcy Code. The Parties further agree that, in the event of the
commencement of a bankruptcy proceeding by or against Celera under the U.S.
Bankruptcy Code, MMI shall be entitled to a complete duplicate of (or complete
access to, as appropriate) any such intellectual property and all embodiments of
such intellectual property, and same, if not already in their possession, shall
be, within ten (10) days of the commencement of such proceeding, delivered to
them (a) upon any such commencement of a bankruptcy proceeding upon their
written request therefore, unless Celera (or a trustee on behalf of Celera)
elects to continue to perform all of their obligations under this Agreement or
(b) if not delivered under (a) above, upon the rejection of this Agreement by or
on behalf of Celera upon written request therefore by MMI. Nothing herein shall
constitute MMI's acquiescence or agreement that all or any portion of this
Agreement is subject to rejection

        9.5     Consequences of Termination. Upon termination of this Agreement:

                (a)     The following provisions shall survive: Article 4
(Payments); Article 7 (Confidentiality and Publication); Article 9 (Term and
Termination); Article 11 (Disclaimers and Limitation of Liability); Article 12
(Indemnity) and Article 13 (General Provisions). Notwithstanding Sections 9.5(b)
and 9.5(c), Sections 6.1 and 6.2 shall survive termination of this Agreement.

                                       16
<PAGE>

                (b)     In the event of termination of this Agreement by reason
of MMI's Default, MMI shall pay, within thirty (30) days following written
notice of termination an amount equal to any amount due and payable as of the
date of such termination.

                (c)     In the event of termination of this Agreement by reason
of Default by Celera, subject to the payment of all fees due and payable prior
to the date the Default occurred, all licenses granted to MMI hereunder shall
continue in full force and effect for the time period anticipated by the most
recent payment made by MMI.

        9.6     Remedies. The rights and remedies provided in this Article 9
shall not be exclusive and shall be in addition to any other rights and remedies
available at law or in equity.

                                   ARTICLE 10

              REPRESENTATIONS AND WARRANTIES AND RELATED CONVENANTS

        10.1    Each Party represents to the other Party as of the Effective
Date and thereafter, that, to the best of its knowledge:

                (a)     it is duly organized and validly existing and in good
standing under the laws of the jurisdiction of its incorporation and it has the
corporate power and authority and the legal right to enter into this Agreement
and to perform its obligations hereunder;

                (b)     the execution and delivery of this Agreement and the
performance of the transactions contemplated hereby have been duly authorized by
all necessary corporate actions of such Party and the person executing this
Agreement on behalf of each Party has been duly authorized to do so by all
requisite corporate actions;

                (c)     the execution and delivery of this Agreement and the
performance by such Party of any of its obligations under this Agreement does
not (i) conflict with, or constitute a breach or violation of, any other
contractual obligation to which it is a Party, any judgment of any court or
governmental body applicable to such a Party or its properties or, to the best
of such Party's knowledge, any statute, decree, order, rule or regulation of any
court or governmental agency or body applicable to such Party or its properties,
and (ii) with respect to the execution and delivery of this Agreement, require
any consent or approval of any Third Party;

                (d)     it is aware of no action, suit or inquiry or
investigation contemplated or instituted by any Third Party that questions or
threatens the validity of this Agreement; and

                (e)     this Agreement is legally binding upon its execution
and, subject to the discretion of courts in awarding equitable relief and to
applicable bankruptcy, reorganization, insolvency, moratorium, and similar laws,
enforceable in accordance with its terms.

                                       17
<PAGE>

        10.2    Each Party shall (a) comply with all applicable laws,
regulations and guidelines in connection with that Party's performance of its
obligations and exercise of its rights pursuant to this Agreement, (b) maintain
good standing under the laws of the jurisdiction of its incorporation, and (c)
not enter into any contractual obligation that would conflict with or constitute
a breach or violation of any material provision of this Agreement.

                                   ARTICLE 11

                     DISCLAIMERS AND LIMITATION OF LIABILITY

        11.1    NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION
MADE OR WARRANTY GIVEN BY CELERA OR ITS SUPPLIERS THAT THE USE OF ANY
INFORMATION, DATA, SOFTWARE OR OTHER MATERIALS PROVIDED HEREUNDER WILL NOT
INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF ANY THIRD PARTY.
THE INFORMATION, DATA, SOFTWARE AND OTHER MATERIALS PROVIDED BY CELERA HEREUNDER
ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND WHATSOEVER, EXPRESS OR
IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE. CELERA MAKES NO WARRANTY THAT THE PRODUCTS WITHIN THE BPP
SUBSCRIPTION DO NOT CONTAIN ERRORS.

        11.2    IN NO EVENT SHALL CELERA (OR CELERA'S SUPPLIERS) OR MMI (OR
MMI'S CUSTOMERS OR SUBLICESEES) BE LIABLE FOR LOST PROFITS, LOSS OF USE, LOSS OF
BUSINESS, BUSINESS INTERRUPTION, LOSS OF DATA, COST OF COVER OR ANY INDIRECT,
SPECIAL, CONSEQUENTIAL OR INCIDENTAL DAMAGES OF ANY NATURE WHATSOEVER, HOWEVER
CAUSED AND UNDER ANY THEORY OF LIABILITY WHETHER BASED IN CONTRACT, WARRANTY,
TORT, STRICT LIABILITY, STATUTORY OR OTHERWISE, ARISING OUT OF OR IN CONNECTION
WITH THIS AGREEMENT EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES.

        11.3    THE LIABILITY OF CELERA OR MMI, AND THEIR RESPECTIVE AGENTS,
EMPLOYEES, SUBCONTRACTORS, SUPPLIERS, CUSTOMERS AND SUBLICENSEES WITH RESPECT TO
ANY AND ALL SUITS, ACTIONS, LEGAL PROCEEDINGS, CLAIMS, DEMANDS, DAMAGES, COSTS
AND EXPENSES ARISING OUT OF THE PERFORMANCE OR NONPERFORMANCE OF ANY OBLIGATIONS
UNDER THIS AGREEMENT, WHETHER BASED ON CONTRACT, WARRANTY, TORT, STRICT
LIABILITY, STATUTORY OR OTHERWISE, SHALL BE LIMITED TO (a) DIRECT, ACTUAL
DAMAGES INCURRED AS A RESULT OF CELERA'S OR MMI'S FAILURE TO PERFORM ITS
OBLIGATIONS AS REQUIRED BY THIS AGREEMENT, AND (b) SHALL NOT EXCEED, IN THE
AGGREGATE, A SUM EQUAL TO THE TOTAL AMOUNTS PAID TO CELERA UNDER THIS AGREEMENT.

                                       18
<PAGE>

        11.4    NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN, ANY
MMI TECHNOLOGY DISCOVERED THROUGH MMI'S AUTHORIZED USE OF THE BPP PRODUCTS AND
TECHNOLOGY MAY BE SUBJECT TO CELERA'S INTELLECTUAL PROPERTY RIGHTS IN CELERA
TECHNOLOGY AND/OR THE INTELLECTUAL PROPERTY RIGHTS OF A THIRD PARTY.

                                   ARTICLE 12

                        INDEMNITY, DAMAGES AND INSURANCE

        12.1    MMI Indemnity. MMI shall indemnify, defend and hold harmless
Celera (including its officers, directors, employees and agents) from and
against all personal or property losses, liabilities, damages and expenses
(including attorneys' fees and costs) arising from a claim of a Third Party (a)
out of the falsehood or inaccuracy in any material respect of any representation
or warranty or out of the breach or non-fulfillment of any material covenant or
agreement of MMI contained herein or contemplated hereby; or (b) out of the
gross negligence or intentional misconduct of MMI in connection with the
performance of MMI of its obligations under this Agreement; or (c) out of MMI's
use of MMI Technology; or (d) from products developed by MMI under the license
granted in Article 2; except to the extent any such loss, liability, damage or
expense arises from the action or inaction of Celera.

        12.2    Celera Indemnity. Celera shall indemnify, defend and hold
harmless MMI (including its officers, directors, employees and agents) from and
against all personal or property losses, liabilities, damages and expenses
(including attorneys' fees-and costs) arising from a claim of a Third Party (a)
out of the falsehood or inaccuracy in any material respect of any representation
or warranty or out of the breach or non-fulfillment of any material covenant or
agreement of Celera contained herein or contemplated hereby, or (b) out of the
gross negligence or intentional misconduct of Celera in connection with the
performance of its obligations under this Agreement; except to the extent any
such loss, liability, damage or expense arises from the action or inaction of
MMI.

        12.3    Procedure. The Indemnitee shall promptly notify the Indemnitor
of any loss, liability, damage, expense, claim, demand, action or other
proceeding in respect of which the Indemnitee intends to claim such
indemnification, and the Indemnitor shall have the right to participate in, and,
to the extent the Indemnitor so desires, jointly with any other indemnitor
similarly noticed, to assume the defense thereof with counsel selected by the
Indemnitor and reasonably satisfactory to the Indemnitee; provided, however,
that an Indemnitee shall have the right to retain its own counsel, with the fees
and expenses to be paid by the Indemnitee, if representation of such Indemnitee
by the counsel retained by the Indemnitor would be inappropriate due to actual
or potential differing interests between such Indemnitee and any other Party
represented by such counsel in such proceedings. The indemnity agreement in this
Article 12 shall not apply to amounts paid in settlement of any loss, liability,
damage, expense, claim, demand, action or other proceeding if such settlement
shall be effected without the consent of the

                                       19
<PAGE>

Indemnitor, which consent shall not be withheld unreasonably. The failure to
deliver notice to the Indemnitor within a reasonable time after the commencement
of any such action, if prejudicial to its ability to defend such action, shall
relieve such Indemnitor of any liability to the Indemnitee under this Article 12
to the extent Indemnitor is prejudiced by Indemnitee's delay, but the omission
so to deliver notice to the Indemnitor will not relieve it of any liability that
it may have to the Indemnitee otherwise than under this Article 12. The
Indemnitor may not settle the action or otherwise consent to an adverse judgment
in such action or other proceeding that effects the rights or interests of the
Indemnitee without the express written consent of the Indemnitee, which consent
shall not be unreasonably withheld or delayed. The Indemnitee under this Article
12, and its employees and agents, shall cooperate fully with the Indemnitor and
its legal representatives in the investigation of any action, claim or liability
covered by this indemnification.

        12.4    Damages Payable in Cash and Stock. In the event Celera is
obligated to pay damages to MMI by way of final judgment in any suit at law or
in equity or in settlement of any dispute arising out of this Agreement,
excluding any indemnity of MMI pursuant to Section 12.2, which indemnity shall
be satisfied in cash, Celera shall have the option, but not the obligation, to
satisfy such obligation, in whole or in part, by delivering to MMI for the
benefit of MMI, that number of shares of Series E Convertible Preferred Stock or
shares of common stock of MMI ("Common Stock") issued to Celera upon the
conversion of such Series E Convertible Preferred Stock. Notwithstanding the
preceding sentence, if Celera has received cash payments pursuant to Section
4.1(b) and/or Section 6.3, Celera will first satisfy any such obligation in cash
up to such amount received and thereafter in stock as set forth in the preceding
sentence. For the purpose of this Section 12.4, the value of each share of
Series E Convertible Preferred Stock or Common Stock, as the case may be,
delivered to MMI pursuant to this Section 12.4 shall be $17.50 per share
adjusted to take into account any stock splits, reorganizations and
recapitalizations, as well as any other anti-dilution adjustments pursuant to
the Certificate of Designations. To the extent Celera does not satisfy any
indemnification obligations by delivering shares of Series E Convertible
Preferred Stock or Common Stock, Celera shall satisfy such indemnification
obligations in cash.

        12.5    Insurance. Each Party will maintain, through self-insurance or
commercially placed insurance, adequate coverage for the non-contractual
indemnification obligations set forth herein, including without limitation, in
respect to suits, actions, claims, demands, damages, costs and expenses arising
out of the use of Agricultural Products and Services by Third Parties. Each
Party may request in writing the other Party to provide proof of adequate
insurance.

                                   ARTICLE 13

                               GENERAL PROVISIONS

        13.1    No Partnership. Nothing in this Agreement is intended or shall
be deemed to constitute a partnership, agency, distributorship,
employer-employee or joint venture

                                       20
<PAGE>

relationship between MMI and Celera. No Party shall incur any debts or make any
commitments for the other, except to the extent, if at all, specifically
provided herein.

        13.2    Assignments. Neither Party shall assign any of its rights or
obligations hereunder in whole or in part, except: (a) as incident to the
merger, consolidation, reorganization or acquisition of stock or assets or a
similar transaction affecting all or substantially all of the assets or voting
control of the assigning Party (or, in respect to MMI, a sale of a
species-specific business); (b) to any directly or indirectly wholly-owned
subsidiary if the assigning Party remains liable and responsible for the
performance and observance of all of the subsidiary's duties and obligations
hereunder; or (c) with the consent of the other Party, such consent not to be
unreasonably withheld or delayed. This Agreement shall be binding upon the
successors and permitted assigns of the Parties, and the name of a Party
appearing herein shall be deemed to include the names of such Party's successors
and permitted assigns to the extent necessary to carry out the intent of this
Agreement. Any assignment not in accordance with the above shall be void.

        13.3    Further Actions. The Parties agree to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

        13.4    No Trademark Rights. Except as otherwise provided herein or
agreed to in advance in writing, no right, express or implied, is granted by
this Agreement to use in any manner the names "Celera," "Celera Genomics," "PE
Corporation," "Applera," or "MetaMorphix" or any other trade name or trademark
of a Party or the names of any employees thereof, for any purpose other than for
the Parties' own internal purposes.

        13.5    Public Announcements. Except as may otherwise be required by law
or regulation, neither Party shall make any public announcement, directly or
indirectly, concerning the terms of this Agreement or the subject matter hereof
without first submitting a copy of the proposed announcement to the other Party
for review and obtaining the approval of the other Party. With the exception of
an initial public announcement concerning the existence or terms of this
Agreement or the subject matter hereof, the reviewing Party shall have thirty
(30) days or such other time as mutually agreed upon to consent to the
publication of such announcement, such consent not to be unreasonably withheld.
The reviewing Party shall have seven (7) business days or such other time as
mutually agreed upon to consent to the publication of such initial public
announcement, such consent not to be unreasonably withheld. If either Party
shall be required by law or regulation to make a public announcement concerning
the existence or terms of this Agreement, such Party shall give at least twenty
four (24) hours prior advance notice of the proposed text of such announcement
to the reviewing Party for its prior review and comment.

        13.6    Entire Agreement of the Parties; Amendments. This Agreement,
including its Schedules and Exhibits constitute and contain the entire
understanding and agreement of the Parties and cancels and supersedes any and
all prior negotiations, correspondence, representations, understandings and
agreements, whether verbal or

                                       21
<PAGE>

written, between the Parties respecting the subject matter hereof. No waiver,
modification or amendment of any provision of this Agreement shall be valid or
effective unless made in writing and signed by a duly authorized representative
of each Party. The failure or delay of either Party in enforcing any of its
rights under this Agreement shall not be deemed a continuing waiver or a
modification by such Party of such right.

        13.7    Severability. In the event any one or more of the provisions of
this Agreement should for any reason be held by any court or authority having
jurisdiction over this Agreement or either of the Parties to be invalid, illegal
or unenforceable, such provision or provisions shall be validly reformed to as
nearly as possible approximate the intent of the Parties and, if unreformable,
shall be divisible and deleted in such jurisdiction; elsewhere, this Agreement
shall not be affected so long as the Parties are still able to realize the
principal benefits bargained for in this Agreement.

        13.8    Captions. The captions to this Agreement are for convenience
only, and are to be of no force or effect in construing or interpreting any of
the provisions of this Agreement.

        13.9    Governing Law. This Agreement shall be governed by and
interpreted in accordance with the laws of the State of New York without
reference to the conflict of law principles thereof and without regard to the
United Nations Convention on the International Sale of Goods. Any court action
or proceeding with respect to, or arising out of, this Agreement will, if
brought by either party herein, be instituted and tried only in the state courts
of Montgomery County, Maryland or the U.S. District Court for the District of
Maryland, and both parties hereto waive any right to cause such action or
proceeding to be instituted or tried elsewhere.

        13.10   Notices and Deliveries. Any notice, request, delivery, approval
or consent required or permitted to be given under this Agreement shall be in
writing and shall be delivered personally or sent or by a nationally recognized
overnight courier, costs prepaid, and shall be deemed to have been duly given
when so delivered in person or sent, with receipt confirmed, or one (1) business
day (three (3) business days for international deliveries) after the date of
deposit with such nationally recognized overnight courier. All such notices,
requests, deliveries, approvals, consents or other communications shall be
addressed to the respective Parties at the addresses set forth below, or to such
other address as a Party may designate to the other Party in accordance
herewith.

If to Celera, addressed to:

        CELERA GENOMICS
        45 West Gude Drive
        Rockville, MD 20850
        Attn: Ugo DeBlasi
        Vice President, Finance
        cc: Legal Department

                                       22
<PAGE>

If to MMI, addressed to:

        METAMORPHIX, INC

        1450 South Rolling Road
        Baltimore, Maryland 21227

        Attn: Edwin C. Quattlebaum, Ph.D.
        President and Chief Executive Officer

With a copy to:

        William E. Carlson, Esq.
        Shapiro, Sher & Guinot
        36 S. Charles Street, Suite 2000
        Baltimore, Maryland 21201

        13.11   Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

        13.12   Force Majeure. If the performance of any part of this Agreement
by either Party or of any obligation under this Agreement except the obligation
to pay money, shall be prevented, restricted, interfered with or delayed by
reason of any cause beyond the reasonable control of the Party liable to
perform, unless conclusive evidence to the contrary shall be provided, the Party
so affected shall, upon giving written notice to the other Party, be excused
from such performance to the extent of such prevention, restriction,
interference or delay, provided that the affected Party shall use its
commercially reasonable efforts to avoid or remove such causes of
non-performance and shall continue performance with the utmost dispatch whenever
such causes are removed. When such circumstances arise, the Parties shall
discuss what, if any, modification of the terms of this Agreement may be
required in order to arrive at an equitable solution.

        13.13   Dispute Resolution. Celera and MMI shall deal with each other in
good faith. In the event that a dispute arises between the Parties concerning,
or in any way relating to, this Agreement, the Parties shall undertake good
faith efforts to amicably resolve such dispute.

                (a)     Executive Officers. In the event that the Parties are
unable to resolve any such dispute, the matter shall be referred for further
review and resolution to the Chief Operating Officer, or another designated
representative of Celera, and to the Chief Executive Officer of MMI or MMI's
representative as designated in writing by MMI to Celera, who will attempt in
good faith and reasonable diligence to resolve the dispute.

                (b)     Mediation. If the dispute is not resolved within thirty
(30) days after referral under Section 13.13(a), or such other time as mutually
agreed upon in writing by the Parties, the Parties shall submit the matter to
non-binding mediation to be administered by the AAA under the AAA's Commercial
Mediation Rules. The Party desiring such mediation shall initiate it in
accordance with the AAA's Commercial

                                       23
<PAGE>

Mediation Rules. Upon delivery of the mediation request, the Parties shall
endeavor in good faith to select a neutral mediator who is acceptable to each
Party. If the Parties have not selected a mutually acceptable neutral mediator
within five (5) business days after delivery of the mediation request, they
shall notify the AAA and request the AAA to appoint a mediator in accordance
with the Mediation Rules. Unless otherwise agreed upon by the Parties, all
mediation sessions shall be held at the AAA regional office in the Washington
D.C. metropolitan area. The Parties shall endeavor in good faith to resolve the
dispute through the mediation process contemplated by this Section and neither
Party shall be entitled unilaterally to terminate the mediation prior to thirty
(30) days after the appointment of a mediator.

                (c)     Confidentiality. The Parties hereby mutually agree that
the existence, terms and content of any dispute resolution entered into pursuant
to this Agreement, as well as all information or documents relating thereto,
shall be maintained in confidence and not be given, shown, disclosed to, or
discussed with any Third Party except: (a) by prior written agreement of both
Parties; (b) during any legal proceeding to protect or secure a Party's rights
under such dispute resolution; (c) counsel and accountants who shall agree to
maintain its confidentiality; (d) to the extent required by applicable reporting
requirements; and (e) upon compulsory legal process.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by
their respective duly authorized officers on the date set forth below.

PE CORPORATION (NY), ACTING THROUGH
ITS CELERA GENOMICS GROUP

By:     /s/ Ugo D. DeBlasi
        --------------------
        UGO D. DeBLASI
        ASSISTANT CONTROLLER

Date: February 28, 2002

METAMORPHIX INC.

By:     /s/ Edwin C. Quattlebaum, Ph.D.
        -------------------------------
        Edwin C. Quattlebaum, Ph.D.
        President, Chairman and CEO

Date: February 28, 2002

                                       24
<PAGE>

                                  SCHEDULE 1.9

                  BPP SUBSCRIPTION AND BPP SNP MAP SUBSCRIPTION

    Under the terms and conditions of this Agreement, the Agreement Products
and Technology available under the BPP Subscription and BPP SNP Map Subscription
shall include access to the bovine, porcine and poultry databases and tools as
indicated and further defined below:

DATABASE PRODUCTS

1.  Raw sequence of fragments, quality values, and trace files for bovine,
    porcine and poultry genomes (the "Target Genomes").

        a.  0.75x for bovine
        b.  0.75x for porcine
        c.  1.0x for poultry

2.  Assembly (consensus sequence of contigs, contig quality values, and
    alignments of fragments with contigs) for bovine, porcine, and poultry
    genomes.

SNP MAPS

3.   All SNPs generated through the pipeline for the Target Genomes and the
     region mapped on the human genome (if identified).

        a.  No less than 30,000 unvalidated SNPs per Target Genome,
        b.  No less than 15,000 mapped unvalidated SNPs
        c.  SNP map after validation containing no gaps larger than 0.5 cM.

4.   Human map location of each contig of the Target Genome that maps
     syntenically to the human map.

5.   Identification of known public markers within the target species to Target
     Genome sequence data.

TOOLS

6.   Visualization software that will aid in the selection of appropriate SNPs
     to be included in the final set of validated SNPs spaced approximately 0.5
     cM apart.

7.   Simulation software developed by Celera IR to assist in designing the
     Association Study.

8.  MMI will have a non-exclusive, non-transferable right to use and modify
    source code created by Celera and provided to MMI solely for the purposes of
    creating SNP maps

                                       25
<PAGE>

    for the Bovine Product, Porcine Product and Poultry Product or designing an
    Association Study. Any such modifications or results created using such
    modifications will be delivered to Celera upon request.

TARGET GENOME SPECIFICATION

Sequence Fragments -- as given to the assembler, but in fasta format.

a.  Index files, if any, used to accelerate access to fragments in a large flat
    file.

b.  Quality values for sequence and consensus sequences.

c.  Trace files fragments delivered in tar format on DLT tape, and an index
    specifying which tape contains a particular fragment.

A table or tables describing the sample source that produced each sequence
fragment.

A table or tables describing the mate-pair relationship of the fragments.

Contigs - As produced by the assembly process, specifying consensus sequence

    a.  Files describing the component fragments of each consensus and their
        alignment with the consensus sequence. Documentation on the format of
        this file.

    b.  Index files, if any, used to accelerate access to fragments in a large
        flat file.

SNP MAP SPECIFICATION SNP

Discovery Results -

        a.  All files (including any saved results for the individual stages of
            the SNP discovery process) produced by the SNP pipeline for the
            Target Genomes. The final results must include a set of tables in
            flat files describing the following for each SNP:

                i.  Contig and Start/End offsets

               ii.  Allele Values and Frequencies. Frequencies expressed both as
                    a count of the number of times a value was encountered on a
                    fragment, and an estimate of the frequency of the SNP by
                    chromosome.

              iii.  5' and 3' flanking (consensus) sequence around each SNP.

        b.  Documentation on the format of all the files.

        c.  Documentation on how the SNP discovery process is run, and what
            parameters, if any, were used for the MMI genomes.

                                       26
<PAGE>

SNP Mapping Results -

        a.  All files (including any saved results for the individual stages of
            the SNP mapping process) produced by the SNP mapping pipeline. The
            final results include a set of tables in flat files describing the
            following for each SNP:

                i.  Human Scaffold ID and start/end offsets. ii. Human
                    Chromosome ID and start/end offsets.

        b.  All blast results of the fragments against the human scaffolds,
            either raw (if the pipeline preserves them), or post-processed.

        c.  Documentation on the format of post-processed blast results.

Comparative Genomic Mapping Results --

        a.  All files (including any saved results for the individual stages of
            the mapping process) produced by the Bovine/Porcine/Poultry Genome
            Mapping pipeline. The final results include a set of tables in flat
            files describing the following for each public sequence identified
            as relevant in the mapping project.

                i.  Human Scaffold ID and start/end offsets

               ii.  Human Chromosome ID and start/end offsets

              iii.  Species Chromosome and approximate offset of public
                    sequences where this information is know.

        b.  Blast results, raw and post-processed.

        c.  Documentation of formats used for pipeline results, and intermediate
            files.

Tools Specifications

Map Viewer -

        a.  A standalone version of the Celera Map viewer, and an update of the
Map viewer when comparative genomic viewing is supported.

        b.  Documentation describing the interface requirements of the map
viewer such that MMI will be able to view its own set of mapped SNPs.

Association Study Simulation

        a.  The source and any documentation to a program under development by
the informatics research group that would generate SNP and QTL haplotypes and
genotypes for a simulated population, based on a table of parameters describing
the distribution of the markers, the strength of the genetic component of the
QTL effects, characteristics of the founding population, the number of
generations to simulate, recombination rates, and the reproductive
characteristics of the species being simulated.

                                       27EX-10.21

CONFIDENTIAL TREATMENT REQUESTED: Certain portions of this document have been
omitted pursuant to a request for confidential treatment and, where applicable,
have been marked with an asterisk ("[****]") to denote where omissions have been
made. The confidential material has been filed separately with the Securities
and Exchange Commission.

                                  CONFIDENTIAL

                 JOINT DEVELOPMENT AND JOINT MARKETING AGREEMENT

                                     BETWEEN

            METAMORPHIX, INC. AND EXCEL CORPORATION AND CARGILL, INC.
<PAGE>

                                  CONFIDENTIAL

                 JOINT DEVELOPMENT AND JOINT MARKETING AGREEMENT

This Joint  Development  and Joint  Marketing  Agreement  (the  "Agreement")  is
entered  into  as  of  May  6,  2002  (the  "Effective  Date")  by  and  between
METAMORPHIX,  INC., a Delaware corporation,  having a place of business at 8510A
Corridor Road, Savage, Maryland 20763 ("MMI") and EXCEL CORPORATION,  a Delaware
corporation  and a  subsidiary  of  Cargill,  Incorporated,  having  a place  of
business  at 151 North Main  Street,  Wichita,  Kansas  67202  ("Excel"),  and -
CARGILL,  INCORPORATED,  a Delaware  corporation,  through its Caprock  business
unit, having a place of business at 15407 McGinty Road West, Wayzata,  Minnesota
55391  ("Caprock")(Excel  and Caprock may be collectively  referred to herein as
the "The Cargill Entities"),  each hereinafter  individually  referred to as the
"Party" and collectively as the "Parties."

                                    RECITALS
                                    --------

        WHEREAS,  MMI has  developed  and licensed in resources and expertise in
the areas of on-line information,  discovery sciences,  discovery services,  and
agricultural  products  that are  based on MMI's  generation,  integration,  and
analysis of biological  information  and that enable  agricultural  research and
discoveries by the members of the agriculture  industry and research  community;
and

        WHEREAS, Excel is engaged in the business of processing cattle and other
livestock into various meat and  animal-derived  products,  and the sale of such
products; and

        WHEREAS,  Caprock is engaged in the business of raising and feeding beef
cattle; and

        WHEREAS,  The Cargill  Entities,  subject to the terms and conditions of
this Agreement,  desire to have MMI perform the discovery  services as described
in this Agreement for them, and MMI desires to obtain  certain  information  and
data from The Cargill Entities as described in this Agreement; and

        WHEREAS,  The Cargill  Entities and MMI intend to work  together  toward
jointly developing and jointly commercializing  products through the utilization
of the discovery  services,  information,  and data that are the subject of this
Agreement; and

        WHEREAS, MMI, subject to the terms and conditions of this Agreement,  is
willing to perform the discovery services as set forth in this Agreement for The
Cargill  Entities,  and The  Cargill  Entities,  subject  to the  terms  of this
Agreement, are willing to provide MMI with the information and data as set forth
in this Agreement.

                                       2
<PAGE>

                                  CONFIDENTIAL

                                    AGREEMENT
                                    ---------

        NOW, THEREFORE,  the Parties agree, covenant,  represent, and warrant as
follows:

                                  1 DEFINITIONS

For  purposes  of this  Agreement,  each  capitalized  term used  shall have the
meaning assigned to it in Exhibit A or otherwise in this Agreement.

                2   PERFORMANCE AND GOVERNANCE OF THE WORK PLAN

2.1     PRIMARY  CONTACTS AND STEERING  COMMITTEE.  The Parties shall form a six
        (6) person steering committee (the "Steering  Committee") to monitor the
        research and development activities under this Agreement and perform the
        functions as provided  below.  MMI and The Cargill  Entities  each shall
        appoint three (3)  representatives  to serve on the Steering  Committee,
        and each shall  designate one of its  representatives  to be the primary
        contact  between  them  and to serve as the  co-chairs  of the  Steering
        Committee.  These primary  contacts shall be responsible  for day-to-day
        communication  between  the  Parties  and for  preparing  and  retaining
        summaries of all  communications  for at least three (3) years after the
        date of Complete  Delivery.  Each Party may substitute any or all of its
        representatives  to the Steering  Committee  upon written  notice to the
        other Party. Prior written notice (of at least three (3) days and to all
        members) must be given of all meetings (whether held in person or by
        telephone conference), at least four (4) members of the Steering
        Committee must be present to constitute a quorum, and any decisions,
        recommendations, or other authorized actions of the Steering Committee
        shall be made only by a majority vote of all six members of the
        Committee (i.e., by at least four (4) members voting in the
        affirmative).

        2.1.1   The Steering Committee shall:

                (a)     Monitor  issues  relating  to the Work  Plan  (which  is
                        attached to this Agreement as Exhibit B and incorporated
                        by reference herein) and to the Joint IP.

                (b)     Monitor,  discuss,  and make  recommendations on matters
                        relating to Joint IP (including, but not limited to, the
                        advisability  of  filing  a  patent  upon  any  specific
                        association or other item of Joint IP);

                (c)     Assess the research requirements,  time frames, and work
                        prioritization of the Work Plan. The Steering  Committee
                        shall have the authority to extend any deadlines or time
                        frames  under the Work Plan by no more than  sixty  (60)
                        days.  Should  either Party seek an extension  beyond 60
                        days, it must be approved in writing

                                       3
<PAGE>

                                  CONFIDENTIAL

                        by the Chief Executive Officer of MMI (or his authorized
                        designee) and the  designated  Business  Manager for The
                        Cargill Entities.

                (d)     Meet following the completion or purported completion of
                        each Part of the Work  plan,  within  30 days  following
                        delivery by MMI to The Cargill  Entities of the required
                        Deliverable(s) applicable to such Part of the Work Plan,
                        to (1)  discuss and assess the  Deliverable(s),  and (2)
                        make a  recommendation  as to whether or not the Parties
                        should proceed to the next Part of the Work Plan. In the
                        event that the  recommendation of the Steering Committee
                        is to  proceed  to the next Part of the Work  Plan,  the
                        Parties shall so proceed. In the event that the Steering
                        Committee recommends that the Parties not proceed to the
                        next Part or in the event  that the  Steering  Committee
                        cannot reach a majority  vote on the issue,  the Parties
                        shall follow the procedure set forth in Section 12.12.

                (e)     Following   completion  of  the  Work  Plan,   turn  its
                        attention and efforts  toward  commercialization  of the
                        Joint IP and associated  products and services.  In this
                        regard,  the Steering  Committee shall,  keeping in mind
                        the  Core  Commercialization  Concepts  (as  defined  in
                        Section 8), meet on a regular basis to discuss, evaluate
                        alternatives,  and make recommendations  relating to the
                        commercialization of the Joint IP and the execution of a
                        definitive Joint Commercialization Agreement.

        2.1.2   The Steering Committee shall NOT have any authority to:

                (a)     amend the Work  Plan,  other  than with  respect  to the
                        extension  of  deadlines  as  specifically  described in
                        Section 2.1.1(d) above;

                (b)     amend this Agreement; or

                (c)     bind any of the Parties to any  obligation or commitment
                        in addition to or different from those contained in this
                        Agreement.

2.2     WORK PLAN. The Parties shall use their  commercially  reasonable efforts
        to complete the research and  activities  in the Work Plan in accordance
        with the schedule set forth therein.

2.3     MATERIAL, DATA AND/OR INFORMATION TRANSFER.

        2.3.1   The Cargill  Entities  shall provide MMI with the Samples in the
                amount and of the  quality set forth in the Work Plan for MMI to
                use for purposes set forth in this Agreement and to complete the
                Work Plan.  The  Cargill  Entities  further  shall  describe  in
                writing  each  transfer  of any Sample to MMI. In the event that
                The Cargill  Entities fail to deliver the Samples as required by
                the Work  Plan,  then MMI shall  provide  written  notice to The
                Cargill  Entities'  co-chair of the Steering  Committee  and the
                time for MMI

                                       4
<PAGE>

                                  CONFIDENTIAL

                to provide each affected  Deliverable  and Complete  Delivery to
                Excel  shall be extended by a number days equal to the number of
                days that  passed from the due date for such  Samples  until the
                date that The Cargill Entities delivered the required Samples to
                MMI.

        2.3.2   MMI shall (a) use The Cargill Entities'  Material solely to meet
                its  obligations  under  this  Agreement,  and (b) either (i) if
                requested by The Cargill Entities in timely fashion,  return all
                residual  Samples  to The  Cargill  Entities  (or  another  site
                designated by The Cargill  Entities') at the expense and risk of
                The Cargill  Entities within thirty (30) calendar days after the
                date of Complete  Delivery or  termination  of this Agreement or
                (ii) destroy all residual  Samples  within  thirty (30) calendar
                days after the date of Complete  Delivery or termination of this
                Agreement. MMI shall not distribute, release, sell, disclose, or
                otherwise  transfer  the Samples to any Third  Party,  except as
                otherwise may be permitted under Section 4 (Confidentiality).

        2.3.3   The Cargill  Entities  reserve the right to use the Samples and,
                subject  to the terms of this  Agreement,  transfer  them to any
                Third Party.

2.4     DATA ACCUMULATION.  Immediately upon completion of each Part of the Work
        Plan,  MMI  shall  deliver  to  The  Cargill   Entities  the  applicable
        Deliverable(s)  as set  forth  in the  Work  Plan and  Section  3.2.  In
        addition,  MMI shall record and store the data and  information as it is
        generated  and  accumulated  under the Work Plan in one or more computer
        databases in anticipation of the delivery of certain  confidential  data
        and information in furtherance of Section 7.8.

                                     3       PAYMENTS

3.1     PAYMENTS BY THE  CARQILL  ENTITIES TO MMI.  The Cargill  Entities  shall
        share in the costs of the activities and services performed by MMI under
        the Work  Plan by making  payments  to MMI as set  forth in  Exhibit  C.
        Except for the Initial Payment, it is the intent of the Parties that The
        Cargill  Entities shall be obligated to make a given payment to MMI only
        following  the full and  successful  completion of each Part of the Work
        Plan upon delivery by MMI of the required Deliverable(s).

3.2     MMI DELIVERY OF DELIVERABLE(S).  When MMI believes that it has completed
        a given Part of the Work Plan, it shall deliver to The Cargill  Entities
        the required  Deliverable(s) which shall be accompanied by (1) a written
        statement confirming that all of the required actions and services under
        the  Work  Plan  have  been  completed  and  that  all of  the  required
        Deliverable(s) have been delivered and (2) an invoice for the applicable
        payment amount as set forth on Exhibit C.

3.3     REVIEW OF DELIVERABLE(S) BY THE CARQILL ENTITIES.  Upon receipt from MMI
        of all of the Deliverable(s) and the written documentation described in
        Section 3.2, The Cargill Entities shall have a period of thirty (30)
        days to examine the Deliverables

                                       5
<PAGE>

                                  CONFIDENTIAL

        and make a determination, in its reasonable judgment, as to whether MMI
        has completed all of the required actions and services and delivered all
        of the required Deliverable(s).

        3.3.1   In the  event  that  The  Cargill  Entities  determine  that all
                required  Deliverable(s) have been successfully  delivered,  The
                Cargill Entities shall remit payment to MMI within ten (10) days
                following the 30 day period  evaluation  period. If such payment
                is not received on or before such tenth (10th) day, then MMI may
                provide written notice to The Cargill Entities'  co-chair of the
                Steering  Committee  and have the  time for MMI to  provide  the
                Deliverable(s)  for the  next  Part of the  Work  Plan  shall be
                extended  by a number of days  equal to the  number of days that
                passed  from the due date for such  payment  until the date upon
                which MMI receives such payments.

        3.3.2   In the  event  that  The  Cargill  Entities  determine  that all
                required Deliverable(s) have not been delivered, (1) The Cargill
                Entities shall advise MMI in writing of its determination within
                the 30 day evaluation period specifying, in detail, the areas of
                deficiency and (2) The Cargill Entities' obligation to remit the
                applicable payment and MMI's obligation to proceed with the next
                Part of the Work Plan shall be suspended pending a resolution of
                the matter as described in Section 3.3.3 below.

        3.3.3   In the event The Cargill Entities provide written notice to MMI
                of deficiencies as described in Section 3.3.2 above, MMI shall
                either:

                (a)     make an effort to address the deficiencies  cited by The
                        Cargill  Entities and make a corrective  delivery of all
                        of the required  Deliverable(s) within 30 days following
                        receipt of The Cargill  Entities'  notice, in which case
                        Cargill  shall have a further 30 day period to  evaluate
                        the  corrective  Deliverable(s).  In the event  that The
                        Cargill Entities determine,  in its reasonable judgment,
                        that all required  Deliverable(s)  have been  delivered,
                        The Cargill Entities,  shall remit payment to MMI within
                        ten (10) days  following  the  earlier of the end of the
                        30-day period evaluation  period or such  determination.
                        In the event The Cargill  Entities again  determine that
                        all required Deliverable(s) have not been delivered, (1)
                        The Cargill  Entities shall advise MMI in writing of its
                        determination  within the new 30-day  evaluation  period
                        specifying the areas of deficiency,  thereby  initiating
                        one (1)  additional  and final 30-day cure period or (2)
                        if a  reasonable  determination  can be made  that  such
                        Deliverable(s)  are  incapable  of ever being  delivered
                        (due to scientific  impossibility,  impracticability  of
                        the effort,  or MMI's  abandonment of the project),  The
                        Cargill  Entities  shall  thereupon  have  the  right to
                        declare MMI in breach and terminate  this Agreement with
                        immediate effect by providing written notice to

                                       6
<PAGE>

                                  CONFIDENTIAL

                        MMI,  in which case  ownership  and rights in and to the
                        Joint IP shall be as set  forth,  as the case may be, in
                        either  Section  5.3.2 or  Section  7.2.1.  The  Cargill
                        Entities  shall have no further  obligation to remit the
                        applicable payment, nor any further payments whatsoever,
                        to MMI,  subject  to MMI's  right to refer the matter to
                        binding arbitration in accordance with Section 12.12; or

                (b)     advise  The  Cargill  Entities  in  writing  (i) that it
                        disagrees with The Cargill Entities notice, (ii) that it
                        reasserts  that  its  belief  that  all of the  required
                        Deliverable(s)  have been  delivered,  and  (iii)  while
                        reserving the right to delivery  additional or different
                        Deliverable(s),  that it is  submitting  the  matter  to
                        binding arbitration in accordance Section 12.12.

3.4     NONREFUNDABLE   NATURE.  All  payments  made  by  The  Cargill  Entities
        hereunder  are  nonrefundable,  but the  making of any  payments  by The
        Cargill  Entities to MMI shall in no way prevent or preclude The Cargill
        Entities  from  seeking,  pursuing,  and/or  recovering  any  rights and
        remedies available under this Agreement.

3.5     TAXES.  All amounts  payable  under this  Agreement are exclusive of all
        sales, use,  value-added,  withholding,  and other taxes and duties. The
        Cargill  Entities shall pay all sales and use taxes and duties  assessed
        in connection  with the sale of products to or  performance  of services
        for The Cargill Entities under this Agreement and its performance by any
        authority  within or outside  of the U.S.  The  Parties  shall be solely
        responsible  for the  payment  of any and all  taxes  payable  on  their
        respective net income and the payment of any and all employment  related
        taxes   attributable  to  their  respective   employees,   agents,   and
        representatives.

3.6     FAILURE BY THE CARQILL ENTITIES TO MAKE TIMELY PAYMENT.

        3.6.1   NOTICE  AND RIQHT TO  TERMINATE.  In the event  that MMI has not
                received  a payment  from The  Cargill  Entities  due  hereunder
                within the  prescribed  time period in violation of the terms of
                this Agreement, MMI shall notify The Cargill Entities in writing
                of such  non-payment.  In the  event  that MMI has not  received
                payment  within  fifteen (15) days after  receipt by The Cargill
                Entities of such  notice  from MMI,  MMI shall have the right to
                suspend  further  work under the Work Plan  and/or  suspend  The
                Cargill Entities' rights to the Joint IP. In the event that such
                payment  is not made  within  thirty  (30)  days of The  Cargill
                Entities' receipt of such notice,  MMI also shall have the right
                to declare The Cargill  Entities in default and  terminate  this
                Agreement with immediate  effect by providing  written notice to
                The Cargill  Entities in  accordance  with Section 7.2, in which
                case  ownership  and rights in and to the Joint IP and liability
                of The Cargill Entities shall be as set forth in Section 7.2.

                                       7
<PAGE>

                                  CONFIDENTIAL

        3.6.2   LATE PAYMENT FEE. Any payment due under this  Agreement  that is
                not paid within the  specified  time period in  violation of the
                terms of this  Agreement,  shall  bear  interest  to the  extent
                permitted by applicable law, at two percentage  points (2%) over
                the prime  rate of  interest  compounded  on an annual  basis as
                reported by Bank of America NT&SA in San Francisco,  California,
                from time to time, calculated on the number of days such payment
                is delinquent.

                      4       CONFIDENTIALITY AND PUBLICATION

4.1     CONFIDENTIALITY.   The  Parties  acknowledge  that  the  Confidentiality
        Agreements  shall control all disclosures  from its effective date up to
        and until the Effective Date of this  Agreement.  The Parties agree that
        each Confidentiality  Agreement is hereby superseded as of the Effective
        Date of this  Agreement  by the terms and  conditions  set forth in this
        Section 4 and the other  applicable  terms and  conditions  set forth in
        this Agreement.

        4.1.1   The Parties acknowledge that during the course of this Agreement
                they may each receive  (and hence  become a  "Receiving  Party")
                from   the   other   (the   "Disclosing    Party")   information
                electronically,  in  writing,  or  orally,  that is  proprietary
                and/or  confidential  and of commercial  value to the Disclosing
                Party.  The  Parties  agree that they shall take all  reasonable
                measures  to protect  the  secrecy of and avoid  disclosure  and
                unauthorized  use  of  the  Confidential  Information.   Without
                limiting the  foregoing,  the Parties  shall take at least those
                measures  that  each  takes  to  protect  its  own  confidential
                information  of a similar  nature,  but in no event  less than a
                reasonable degree of care. Both Parties shall immediately notify
                the  other  in the  event  either  Party  has  knowledge  of any
                unauthorized use or disclosure of the Confidential Information.

        4.1.2   Except to the extent expressly authorized by this Agreement, the
                Parties agree that the Receiving  Party shall keep  confidential
                and shall not publish or otherwise  disclose,  and shall not use
                for any purpose, any Confidential Information furnished to it by
                the Disclosing  Party pursuant to this Agreement,  regardless of
                the medium on which it is provided,  including know-how,  except
                to the extent that it can be established by the Receiving  Party
                by competent proof that such information:

                (a)     was already  known to the  Receiving  Party,  other than
                        under an obligation of  confidentiality,  at the time of
                        disclosure by the Disclosing Party;

                (b)     was generally  known to the public or otherwise  part of
                        the public  domain at the time of its  disclosure to the
                        Receiving Party;

                (c)     became  generally  available  to the public or otherwise
                        part of the public domain after its  disclosure  through
                        no fault of the Receiving Party;

                                       8
<PAGE>

                                  CONFIDENTIAL

                (d)     was  subsequently  lawfully  disclosed to the  Receiving
                        Party by a Third Party who did not require the Receiving
                        Party  to  hold  it in  confidence  or  limit  its  use,
                        provided  it was not  obtained by such Third Party under
                        an obligation of confidentiality  directly or indirectly
                        from the Disclosing Party; or

                (e)     was   independently   discovered  or  developed  by  the
                        Receiving  Party  without  the  use  of  the  Disclosing
                        Party's Confidential  Information,  as can be documented
                        by  written   records   created  at  the  time  of  such
                        independent discovery or development.

4.2     PERMITTED DISCLOSURE.

        4.2.1   Subject to Section  4.1,  the  Receiving  Party may disclose the
                Disclosing Party's  Confidential  Information only to the extent
                such disclosure is required for complying with applicable  laws;
                regulations,  and/or court or  administrative  orders;  provided
                however,  that in each case described in this Section 4.2.1, the
                Receiving Party shall (i) give at least  twenty-four  (24) hours
                advance  notice  to the  Disclosing  Party  of  such  disclosure
                requirement; (ii) provide a copy of the proposed disclosure; and
                (iii) use  commercially  reasonable  efforts  in  assisting  the
                Disclosing Party to secure confidential  treatment,  including a
                protective order, for such Confidential  Information required to
                be disclosed.

        4.2.2   The  Receiving   Party  may  disclose  the  Disclosing   Party's
                Confidential   Information   only  to  the   Receiving   Party's
                employees, contractors, consultants, or licensees who (a) have a
                need-to-know  and (b) are under  contract not to disclose or use
                Confidential  Information  except as otherwise  provided in this
                Agreement.

4.3     COPIES.  A Receiving  Party shall not make any copies of the  Disclosing
        Party's  Confidential  Information without the prior written approval of
        the  Disclosing  Party,  except  that,  subject to Section  7.2, (a) The
        Cargill  Entities may make copies that are reasonably  necessary for the
        research and development of The Cargill Entities' Products,  (b) MMI may
        make copies that are  reasonably  necessary  for the conduct of the Work
        Plan, and (c) copies may be made as a part of any effort by the Steering
        Committee  or as a part of the  planning  for  joint  commercialization.
        Notwithstanding  the foregoing,  the Receiving  Party may retain one (1)
        copy of the Disclosing Party's Confidential Information solely for legal
        archival purposes.

4.4     PUBLICATION.  Any  Publications  shall not include any of the Disclosing
        Party's  Confidential  Information  without the Disclosing Party's prior
        written consent and shall include  appropriate  recognition of the other
        Party's  contributions  in  accordance  with the  standard  practice for
        assigning    scientific    credit,    either   through   authorship   or
        acknowledgement as may be appropriate.

                                       9
<PAGE>

                                  CONFIDENTIAL

        4.4.1   JOINT  PUBLICATION.  In the  event  that  the  Parties  agree to
                jointly prepare a Publication of the results of the Work Plan in
                a mutually  acceptable  scientific journal the Parties shall (a)
                jointly   draft   such   Publication    through   the   research
                representatives;  (b) prepare such Publication within a mutually
                agreed upon time following  completion of the Work Plan; and (c)
                have such joint  Publication  reviewed  and approved by the duly
                authorized  officers  of MMI and The Cargill  Entities  prior to
                submission of the article to the agreed upon scientific journal.
                Except  by  mutual  consent,  neither  Party  shall  release  or
                otherwise  transfer any of the results from the Work Plan to any
                Third Party or the public  prior to the date on which such joint
                Publication will be released.

4.5     PUBLIC ANNOUNCEMENTS.

        4.5.1   Except  as may  otherwise  be  required  by  law or  regulation,
                neither  Party shall make any public  announcement,  directly or
                indirectly,  concerning the existence or terms of this Agreement
                (or the  subject  matter  hereof)  without  obtaining  the prior
                consent  of the  other  Party  under  Section  4.5.2;  it  being
                envisioned,  however,  that  there  shall be an  initial  public
                announcement of the existence of this Agreement.

        4.5.2   Unless otherwise agreed upon by the Parties, the reviewing Party
                shall have (a) ten (10)  calendar days to consent (or decline to
                consent)  to  an  initial  public  announcement  concerning  the
                existence  or terms of this  Agreement  (or the  subject  matter
                hereof),  such  consent  not  to  be  unreasonably  withheld  or
                delayed;  or (b)  thirty  (30)  calendar  days to consent to the
                publication of any  announcement  other than those subject to(.)
                (a),  such  consent  not  to  be  unreasonably   withheld.   The
                aforegoing "reasonable" standard of consent shall not apply to a
                proposed public  disclosure of Confidential  Information,  which
                may be  prohibited  by the  Disclosing  Party  in its  sole  and
                absolute discretion.

        4.5.3   If either Party shall be required by law or regulation to make a
                public  announcement  concerning  the existence or terms of this
                Agreement, such Party shall (a) include only such information in
                the public announcement that is specifically  required,  and (b)
                give at least forty-eight (48) hours prior advance notice to the
                other Party and obtain the other Party's comments.

4.6     EQUITABLE  RELIEF.  MMI  and  The  Cargill  Entities  in  their  role as
        Receiving Parties under this Agreement hereby acknowledge and agree that
        with respect to the nature of the Confidential Information, there may be
        no  adequate  remedy  at law for any  breach  of  their  obligations  as
        Receiving Party under the confidentiality  provisions of this Agreement,
        that any such breach may result in  irreparable  harm to the  Disclosing
        Party, and therefore,  notwithstanding Section 12.12, that upon any such
        breach the Disclosing Party shall be entitled to seek equitable  relief,
        in  addition  to  whatever  remedies  it  might  have at law,  including
        injunctive

                                       10
<PAGE>

                                  CONFIDENTIAL

        relief,  specific  performance,  or such other relief as the  Disclosing
        Party may request to enjoin or  otherwise  restrain  any act  prohibited
        hereby,  as well as the recovery of all  reasonable  costs and expenses,
        including attorneys' fees incurred.

                            5       INTELLECTUAL PROPERTY

5.1     MMI RIGHTS AND OBLIGATIONS.  MMI shall own all right, title and interest
        in and to MMI Technology.  MMI shall assume all  responsibility  for all
        costs  associated  with  the  application,   prosecution,   maintenance,
        defense, and enforcement of patent applications and patents claiming all
        or a portion of MMI Technology.

5.2     THE CARGILL ENTITIES RIGHTS AND OBLIGATIONS.  The Cargill Entities shall
        own all  right,  title,  and  interest  in and to The  Cargill  Entities
        Material,  Samples,  and The Cargill  Entities  Technology.  The Cargill
        Entities shall assume all  responsibility  for all costs associated with
        the application,  prosecution,  maintenance, defense, and enforcement of
        patent applications and patents claiming all or a portion of The Cargill
        Entities  Material,  Samples,  and/or The Cargill  Entities  Technology.
        Nothing in this  Agreement  shall  prohibit  The Cargill  Entities  from
        continuing  work under any  agreements  with Third  Parties  relating to
        animal  genomics  research that (1) were signed by The Cargill  Entities
        prior to the  Effective  Date  and (2) do not  require  SNP  association
        analysis.

5.3     JOINT INTELLECTUAL PROPERTY RIGHTS. Except as otherwise provided in this
        Agreement, during the term of this Agreement all Joint IP shall be owned
        jointly by MMI and The Cargill Entities and the following shall apply:

        5.3.1   During the term of this Agreement  (except as may be provided in
                any Joint Commercialization Agreement),  neither Party may enter
                into any negotiations, discussions, or agreements with any Third
                Party regarding any  association  studies in any of the Targeted
                Traits  in bovine  animals  in  respect  to meat  production  or
                processing.  During the Term of this Agreement  and,  subject to
                Section 7.2,  thereafter,  the Parties may not make,  use, sell,
                license,  or  convey  any  rights  in Joint  IP for any  purpose
                whatsoever  (a) except upon joint  agreement  among the Parties,
                (b) except as set forth in Sections 3.3.3, 5.3.2, 7.2.1, or 7.3,
                or (c) except in  furtherance of the Work Plan set forth in this
                Agreement. Neither Party (without the prior written agreement of
                the other Part) may use the Joint IP for comparative studies and
                other uses in other species and,  excluding meat  production and
                processing-related uses, in dairy cattle.

        5.3.2   In  the   event   that   the   Parties   enter   into  a   Joint
                Commercialization  Agreement prior to the expiration of the term
                of this Agreement,  the Parties respective rights and obligation
                with  respect to the Joint IP  thereafter  shall be as stated in
                such Agreement. In the event that

                                       11
<PAGE>

                                  CONFIDENTIAL

                the  Parties  do  not  enter  into  a  Joint   Commercialization
                Agreement prior to the expiration of the Term of this Agreement,
                unless the  provisions of Section 7.2 shall apply,  the Joint IP
                shall  continue  to be  owned  jointly  by MMI and  The  Cargill
                Entities  following the  expiration of this  Agreement with both
                Parties having the right, subject to Section 8.5, to. make, use,
                sell, or sublicense  the Joint IP to detect the Targeted  Traits
                in bovine animals in respect to meat production or processing.

        5.3.3   In no event  shall the rights and  restrictions  established  in
                this Section 5.3 prevent either Party from performing its rights
                and obligations under this Agreement.

        5.3.4   In order to  ensure  the  highest  trade  secret  protection  of
                unpatented  Joint  IP,  in  recognition  of MMI's  research  and
                development efforts among several species, and in recognition of
                the confidential and restricted nature of the databases licensed
                from  Celera,  subject to Section  7.8, MMI shall be entitled to
                maintain complete confidentiality (on a "firewall" basis without
                any access by The Cargill  Entities) of the SNP primer pairs and
                SNP  amplicon  sequence  and  any and all  unpatented  Joint  IP
                relating  to the  SNP  Sets.  Notwithstanding  anything  in this
                Section 5.3.4 to the contrary, The Cargill Entities,  during the
                Term, upon reasonable  written notice of at least two weeks, and
                not more than six times each year, may conduct an on-site review
                of the  firewalled  information.  MMI,  for  cause  shown due to
                conflicting  research efforts,  may delay the on-site review for
                longer than two weeks.

5.4     MMI PATENTS.  All United  States and foreign  patent  applications  that
        pertain to any invention  that is the property of MMI shall be prepared,
        filed, prosecuted, and the sole responsibility of MMI.

5.5     THE CARQILL  ENTITIES  PATENTS.  All United  States and  foreign  patent
        applications  which pertain to any invention that is the property of The
        Cargill  Entities  shall be prepared,  filed,  prosecuted,  and the sole
        responsibility of The Cargill Entities.

5.6     JOINT IP PATENTS. All United States and foreign patent applications that
        pertain to any invention that is Joint IP shall be prepared,  filed, and
        prosecuted  by counsel to be mutually  agreed upon by the Parties at the
        time a decision  is made to file such  joint  application.  The  Parties
        presently  envision a patent and trade secret  strategy  whereby patents
        would be filed upon any  associations of a trait to a specific gene, but
        that patents would not be filed upon any  associations  of a trait to an
        SNP; the latter would be guarded as a highly  confidential trade secret.
        If the Parties  cannot agree with  respect to a particular  issue (e.g.,
        whether to file,  selection  of  counsel),  such issue will be  resolved
        pursuant  to Section  12.12 of this  Agreement.  With regard to Joint IP
        patents, subject to Section 7.2, the

                                       12
<PAGE>

                                  CONFIDENTIAL

        Parties will continue to consult in good faith after the  termination of
        this Agreement for so long as Joint IP patents are being  prosecuted and
        maintained, or such shorter time as mutually agreed to by the Parties in
        writing.  The Parties shall be equally  responsible for all expenses for
        prosecution and maintenance of Joint IP patents (unless  mutually agreed
        to be otherwise by the Parties in writing).

5.7     CELERA. Nothing in this Agreement is intended or shall be interpreted as
        granting  to The  Cargill  Entities  or any  Third  Party  any  right or
        interest in any intellectual  property,  whether licensed to MMI or not,
        (a)  invented,  discovered,   developed,  or  otherwise  created  by  PE
        Corporation  (NY),  or its  Affiliates,  including  the Celera  Genomics
        Group,  or (b)  acquired  or  licensed by PE  Corporation  (NY),  or its
        Affiliates, including for the benefit of the Celera Genomics Group.

5.8     THIRD-PARTY INFRINGEMENT. If MMI believes that the license, transfer, or
        use of the data and  information  in the Dataset  (and,  in turn, in any
        Deliverable  or Joint  IP),  in whole or  part,  infringes  any  patent,
        copyright,  trademark,  or other proprietary right, or if the licensing,
        transfer,  or use of the Dataset, or any part thereof,  is, as a result,
        enjoined, then MMI, in respect to data and information owned or licensed
        by MMI, in its sole  discretion  and  expense,  may: (a) procure for The
        Cargill  Entities and itself the right under such  proprietary  right to
        the Dataset or such part thereof; or (b) replace the data or information
        with  other  non-infringing  data  or  information;  or (c)  remove  the
        infringing data or information,  or part thereof,  and make an equitable
        adjustment  of the  fees  paid  hereunder  as  mutually  agreed  upon in
        writing;  or (d) if such data and  information was received from Cetera,
        endeavor  to cause  Celera to address the  situation.  In respect to any
        such  data and  information  received  from The  Cargill  Entities,  The
        Cargill  Entities  shall  replace  the data or  information  with  other
        non-infringing  data or  information  (and,  to the extent  appropriate,
        agree to such extensions,  additional payments, and the like so that the
        completion of the Work Plan may proceed).

               6       PERIOD OF EXCLUSIVITY FOR FEEDLOT TESTING

6.1     CARGILL  PERIOD OF  EXCLUSIVITY.  Commencing  on the date upon which MMI
        delivers the  Deliverable(s)  required under Part 4 of the Work Plan and
        provided  that (a) The Cargill  Entities make the payment for Part 4 and
        (b) as set forth in Section  8.2, the Parties are  negotiating  toward a
        Joint Commercialization Agreement, and continuing for a period of [****]
        ([****])  months  (the  "Cargill  Period of  Exclusivity"),  The Cargill
        Entities  shall  have  the  exclusive   right,   without  the  right  to
        sublicense,  to make and use of the  Joint IP in its own  operations  to
        detect  the  Targeted  Traits  in  bovine  animals  owned,  grown,  fed,
        purchased,  evaluated for possible purchase,  or processed by either The
        Cargill Entities or any of Excel's "alliance"  partners (as may exist as
        of March 1, 2002  under  Excel's  Alliance  Agreements).  No  "alliance"
        partner  shall  have any  rights  to any Joint IP  (notwithstanding  the
        detection  of  Targeted  Traits  in  such  partner's,   animals)  or  be
        considered as an intended third party beneficiary of this Agreement.

                                       13
<PAGE>

                                  CONFIDENTIAL

6.2     STANDSTILL  IN THIRD PARTY  NEGOTIATIONS.  During the Cargill  Period of
        Exclusivity, MMI shall not enter into any negotiations,  discussions, or
        agreements  regarding  any  association  studies in any of the  Targeted
        Traits in bovine  animals in respect to meat  production  or  processing
        regarding  the Joint IP with any Third  Party,  nor shall  either  Party
        make,  use,  sell,  license,  or  convey  any  rights  in the  Joint IP,
        internally or  otherwise,  except to provide the services to The Cargill
        Entities as described in Section 6.3 or as set forth in Section 5.3.1.

6.3     DNA  COLLECTION  TOOL AND MMI.  SERVICES.  During the Cargill  Period of
        Exclusivity,  The Cargill Entities shall make use of the Joint IP in its
        operations  pursuant  to  this  Section  6.  MMI  shall  provide  a  DNA
        collection tool and the laboratory and/or diagnostic/analytical services
        to The Cargill  Entities  to enable The Cargill  Entities to make use of
        the Joint IP in its own  operations  to detect  the  Targeted  Traits in
        bovine  animals in respect to [****] or [****].  MMI shall  provide such
        tools and  services to The  Cargill  Entities at a fee equal to its cost
        (which  shall  be  determined  by  MMI  in its  reasonable  judgment  in
        accordance with standard  accounting  norms,  but which shall not exceed
        [****] Dollars  ($[****]) per test). Such costs shall be invoiced by MMI
        on a monthly basis and paid by The Cargill  Entities  within thirty (30)
        days. It is the mutual expectation of the Parties that the Joint IP will
        be utilized in a fashion in which The Cargill  Entities  will  collect a
        blood  sample for each animal that The Cargill  Entities  desire to have
        the  Targeted  Traits  detected  and submit that blood sample to MMI for
        analysis using the Joint IP. During the Cargill  Period of  Exclusivity,
        The Cargill  Entities shall submit,  in the  aggregate,  at least [****]
        samples  from  bovine  animals in respect to [****]  (and shall have the
        right to submit up to [****] samples) to MMI, and MMI shall analyze such
        samples.  The Parties  (which shall jointly design the protocols for the
        management of test animals and collection of samples)  envision that the
        submitted samples shall include samples from [****] and from [****].

6.4     BREACHES AND CURES.  In the event that the Cargill Period of Exclusivity
        has commenced (and is continuing) and MMI, thereafter,  fails to provide
        the DNA  collection  tool  and/or  analytical  services  to The  Cargill
        Entities  during the Cargill Period of  Exclusivity  as required,  under
        this Section 6, The Cargill Entities,  subject to and in accordance with
        Section 7.2 and MMI's  failure to cure any breach,  shall have the right
        to (a) retain  another  entity to provide such services and recover from
        MMI any  losses,  damages,  and  expenses  arising  from  MMI's  breach,
        including but not limited to the difference between the fees paid to the
        new service  provider  and the fees that would have been paid to MMI had
        MMI  performed  pursuant  to this  Section,  (b)  extend  the  period of
        exclusivity and for the provision of services by an amount of time equal
        to the delay  caused by MMI (up to an  additional  twelve (12)  months),
        and/or (c) terminate this  Agreement in accordance  with Section 7.3. In
        the event that The  Cargill  Entities  fail to provide MMI with at least
        the minimum number of samples on a regular and continued  basis over the
        [****] ([****]) month Cargill Period of Exclusivity as required under

                                       14
<PAGE>

                                  CONFIDENTIAL

        this Section 6, MMI,  subject to and in accordance  with Section 7.2 and
        the failure of The Cargill  Entities to cure any breach,  shall have the
        right to (a) perform  necessary  and  appropriate  [****] scale  testing
        elsewhere and recover from The Cargill Entities any losses, damages, and
        expenses  arising  from the breach by The  Cargill  Entities  and/or (b)
        terminate this Agreement in accordance with Section 7.3.

                             7       TERM AND TERMINATION

7.1     TERM. Unless terminated earlier as provided herein, this Agreement shall
        be in full force and effect for the Term.

7.2     DEFAULT.  If  either  Party  commits  a  breach  of a  material  term or
        provision of this  Agreement at any time,  and has not cured such breach
        within thirty (30) calendar days after  written  notice  thereof,  which
        notice must state the nature of the breach in  reasonable  detail,  from
        the non-breaching  Party,  then the  non-breaching  Party shall have the
        right to declare the  defaulting  Party in breach and to terminate  this
        Agreement  effective upon written notice thereof to the breaching Party.
        In the event that a claimed  breach is of a nature  that cannot be cured
        within thirty (30) days,  but may reasonably be cured within ninety (90)
        days, the breaching Party (upon notice to the  non-breaching  Party) may
        extend the cure period up to ninety (90) days,  in total,  provided that
        the  breaching  Party  has  promptly  commenced  (and  shall  thereafter
        continue to pursue)  efforts to effect such cure.  (The payment of money
        or the  procurement  of  insurance  shall  never,  by  their  respective
        natures,  be a matter  requiring  a cure of more than thirty (30) days.)
        Any notices  under this Section 7.2 must be  addressed to the  person(s)
        and/or office(s) identified in Section 12.9.

        7.2.1   In the event  this  Agreement  is  terminated  by  either  Party
                pursuant  to  this  Section  7.2,  the  defaulting  Party  shall
                automatically  relinquish  and forfeit all of its rights,  title
                and  interest in and to the Joint IP, and upon such  termination
                all of its rights,  title,  and  interest in and to the Joint IP
                shall  immediately   transfer  to  the   non-defaulting   Party.
                Thereafter,  the  defaulting  Party shall have no right to make,
                sell,  license or convey any rights in Joint IP or use the Joint
                IP for any  purpose  whatsoever,  and the  non-defaulting  Party
                shall have the sole and  exclusive  right to make,  use, sell or
                sublicense the Joint IP to detect the Targeted  Traits in bovine
                animals in respect to meat  production  or processing or for any
                other purpose whatsoever,  including,  without  limitation,  the
                right  to  collaborate   with  other  parties  to  complete  the
                activities contemplated by this Agreement.

        7.2.2   In the event  this  Agreement  is  terminated  by  either  Party
                pursuant to this  Section  7.2,  the  defaulting  Party shall be
                liable  to  the   non-defaulting   party  with  respect  to  all
                obligations arising on or prior to the default by the defaulting
                Party,  but shall not be  liable to the  non-defaulting  for the
                non-

                                       15
<PAGE>

                                  CONFIDENTIAL

                performance  of any  obligations  under this Agreement that were
                due after such  termination,  except for a violation  of Section
                7.2.1. Specifically, for example:

                (a)     in the event that The  Cargill  Entities  fail to make a
                        payment  that  is  due to MMI  in  accordance  with  the
                        provisions  of  Section 3, MMI  shall,  after  providing
                        notice and otherwise  following the procedures set forth
                        in this  Section 7.2,  have the right to terminate  this
                        Agreement,  in which case (i) MMI shall  become the sole
                        owner of the Joint IP in accordance  with Section 7.2.1,
                        and (ii) The Cargill Entities shall remain liable to MMI
                        for the amount of the missed payment,  but shall have no
                        further  liability to MMI for any payments  that were to
                        be made by The  Cargill  Entities to MMI  following  the
                        date of such termination; and

                (b)     in the event  that MMI  fails to  deliver  the  required
                        Deliverable(s) to The Cargill Entities as required under
                        the  Work  Plan,  The  Cargill  Entities  shall,   after
                        providing notice and otherwise  following the procedures
                        set  forth  in this  Section  7.2,  have  the  right  to
                        terminate this Agreement,  in which case (i) The Cargill
                        Entities  shall become the sole owner of the Joint IP in
                        accordance  with Section 7.2.1,  and (ii) MMI shall have
                        no further  liability  to The Cargill  Entities  arising
                        from  non-performance of the remaining Parts of the Work
                        Plan and non-delivery of the Deliverable(s) due from MMI
                        following the-date of such termination.

        Notwithstanding  anything  in this  Section 7.2 to the  contrary,  MMI's
        failure  to  deliver  any   Deliverable(s)   due  to  either  scientific
        impossibility  or  the   impracticability   of  the  effort  (e.g.,  the
        association  study  requiring  substantially  more than the "ten million
        (10,000,000)  genotypes"  maximum  set forth in the Work Plan) shall not
        constitute a breach of this Agreement and the provisions of this Section
        7.2 in regard to termination of this Agreement and ownership of Joint IP
        shall not apply.  Instead,  either (1)  Sections  3.3.3 and 5.3.2 or (2)
        Section 7.4.1 shall govern in such instance.

7.3     RIQHT TO TERMINATE PRIOR TO EXPIRATION OF TERM.  Either Party shall have
        the right to  terminate  this  Agreement,  with or  without  cause,  and
        without further liability to the other Party except as set forth in this
        Section 7.3, in accordance with the following procedures:

        7.3.1   Each Party  shall  have the right to  terminate  this  Agreement
                exercisable at the following time by providing written notice to
                the other Party: following full completion of Part 3 of the Work
                Plan (i.e. after delivery by MMI of the required  Deliverable(s)
                and after the  required  payment by The  Cargill  Entities)  but
                before  commencement  of work under Part 4 of the Work Plan.  In
                addition,   in  the  event  only  that  applicable  Federal  law
                hereafter

                                       16
<PAGE>

                                  CONFIDENTIAL

                prohibits  The  Cargill  Entities  from  owning  or  controlling
                livestock for more than  fourteen  days prior to slaughter  (as,
                for example, set forth in Senate Bill 142 of the 107th Congress,
                1st  Session).  The Cargill  Entities may also have the right to
                terminate this Agreement  exercisable at either of the following
                times by providing  written  notice to MMI: (a)  following  full
                completion of Part 1 of the Work Plan (i.e.,  after  delivery by
                MMI  of the  required  Deliverable(s)  and  after  the  required
                payment by The Cargill Entities, but before commencement of work
                under  Part 2 of  the  Work  Plan)  or (b)  following  the  full
                completion of Part 2 of the Work Plan (i.e.,  after  delivery by
                MMI  of the  required  Deliverable(s)  and  after  the  required
                payment by The Cargill Entities, but before commencement of work
                under Part 3 of the Work Plan).

        7.3.2   In  the  event  that  either  Party  terminates  this  Agreement
                pursuant to this Section 7.3, the Party who elected to terminate
                this   Agreement  in   accordance   with  such   Section   shall
                automatically  relinquish and forfeit all of its rights,  title,
                and  interest in and to the Joint IP, and upon such  termination
                all of its rights,  title,  and  interest in and to the Joint IP
                shall immediately transfer to the other Party.  Thereafter,  the
                Party who  elected  to  terminate  shall  have no right to make,
                sell,  license,  or  convey  any  rights in Joint IP for use the
                Joint IP for any purpose  whatsoever,  and the other Party shall
                have the sole  and  exclusive  right  to  make,  use,  sell,  or
                sublicense the Joint IP to detect the Targeted  Traits in bovine
                animals in respect to meat  production or  processing  including
                the right to  collaborate  with other  parties to  complete  the
                activities contemplated by this Agreement.

        7.3.3   In the event  this  Agreement  is  terminated  by  either  Party
                pursuant to this Section 7.3, the Party who elected to terminate
                shall  continue to be liable to the other Party with  respect to
                all  obligations  arising  on or  prior  to  the  date  of  such
                termination,  but shall not be liable to the other Party for the
                non-performance  of any  obligations  under this  Agreement that
                would  otherwise  have  arisen  after  the date of  termination.
                Specifically,  for  example,  in the event The Cargill  Entities
                elect to terminate this Agreement  pursuant to this Section 7.3,
                (i) MMI shall become the sole owner of the Joint IP and (ii) The
                Cargill  Entities  shall remain  liable to MMI for the amount of
                the missed payment,  but shall have no further  liability to MMI
                for any payments that were to be made by The Cargill Entities to
                MMI  following  the  date of  such  termination  by The  Cargill
                Entities in accordance with this Section 7.3.

7.4     Termination Based on Recommendation of Steering Committee.  If, pursuant
        to Section 2.1.1(d),  the Steering  Committee makes a recommendation not
        to proceed to the next Part of the Work Plan,  the senior  executives of
        the Parties shall meet to discuss the  recommendation  and the following
        shall apply:

                                       17
<PAGE>

                                  CONFIDENTIAL

        7.4.1   In the event that both Parties agree with the  recommendation of
                the Steering  Committee,  the Parties  shall  execute a document
                indicating their decision not to proceed with further work under
                the Work Plan and to jointly  terminate this  Agreement.  Upon a
                termination  of this  Agreement  pursuant to this Section 7.4.1,
                neither Party shall have any further  liability to the other for
                future  obligations  under this Agreement and the Joint IP shall
                continue  to be jointly  owned by MMI and The  Cargill  Entities
                following such  termination,  with both Parties having the right
                to make,  use,  sell or  sublicense  the Joint IP to detect  the
                Targeted  Traits in bovine  animals in respect to  production or
                meat  processing.

        7.4.2   In the event that both Parties disagree with the  recommendation
                of the Steering Committee, the Parties shall confirm their joint
                decision in writing and the  Parties  shall  proceed to the next
                Part of the Work Plan.

In the event one Party concurs with the recommendation of the Steering Committee
and one does not,  the Party that  concurs  with the  recommendation  shall send
written  confirmation of its decision to the other Party and such Party shall be
deemed to have  elected to  terminate  this  Agreement  pursuant  to Section 7.3
above,  with the  Parties  having  the rights  and  obligations  as set forth in
Section 7.3 above.

7.5     BANKRUPTCY.  Either Party may terminate this Agreement  immediately upon
        the  occurrence of any of the following  events:  (a) if the other Party
        ceases to. do business, or otherwise terminates its business operations;
        or  (b)  the  other  Party  seeks   protection   under  any  bankruptcy,
        receivership,   trust  deed,  creditors  arrangement,   composition,  or
        comparable  proceeding,  or if any such proceeding is instituted against
        the other Party.  All rights  granted under this Agreement are deemed to
        be, for purposes of ss.  365(n) of the United  States  Bankruptcy  Code,
        rights to intellectual  property as defined by ss. 101(56) of the United
        States  Bankruptcy  Code  and the  Parties  will  retain  and may  fully
        exercise all of their rights under this Agreement.

7.6     CONSEQUENCES OF  TERMINATION.  Upon  termination of this  Agreement,  in
        addition  to  any  provisions  specifically  addressed  in  any  Section
        regarding  terminations,  the following  provisions shall survive: 4, 5,
        7.6, 7.7, 10, 11, and 12.  Expiration or  termination  of this Agreement
        shall not affect  any rights or  obligations  of either  party  accruing
        prior to such expiration or termination.

7.7     REMEDIES.  The rights and remedies  provided in this Section 7 shall not
        be  exclusive  and shall be in addition to any other rights and remedies
        available at law or in equity.

7.8     ESCROW  OF  FIREWALLED  SNP  SET   INFORMATION.   MMI  shall  provide  a
        third-party escrow agent (reasonably  acceptable to The Cargill Entities
        and under  written  contract  with the  Parties)  with an SNP Set escrow
        deposit  upon the  completion  of Part 1 and,  on an ongoing  up-to-date
        basis upon the completion of each Part

                                       18
<PAGE>

                                  CONFIDENTIAL

        thereafter, such information as would be necessary for a qualified Third
        Party to continue any research and development into the next part of the
        Work  Plan and,  as  envisioned  in  Section  8.1,  to  develop  genomic
        DNA-based diagnostic products. (However, the Parties recognize that MMI,
        in accordance  with Section 5.7, shall not provide the escrow agent with
        any  confidential  information  owned by Cetera  and not part of any MMI
        Technology,  e.g., Celera's bovine SNP maps, database, and technology to
        which MMI has access by virtue of its  license  from  Celera,  but as to
        which MMI has no right to  sublicense.)  Such escrow  agent (as an agent
        for the Partners) shall hold such escrowed confidential information on a
        strict confidentiality basis. Upon a termination of this Agreement under
        Sections  3.3.3,  5.3.2,  7.2.1  (in  the  event  of an MMI  breach  and
        declaration of termination by The Cargill  Entities),  7.3 (in the event
        of MMI's  exercise of a right to terminate  thereunder),  or 7.4.1,  the
        escrow agent (upon at least  fifteen (15) days prior  written  notice by
        The Cargill  Entities to the escrow agent and to MMI) shall release such
        escrowed  information to The Cargill  Entities.  In such event,  MMI may
        challenge by Section 12.12 any such release  (thereby  delaying it). The
        Cargill Entities, upon receipt of any such information shall treat it as
        highly confidential and maintain it as a closely guarded trade secret.

                  8         JOINT COMMERCIALIZATION OF PRODUCTS

8.1     INTENT.  The objective of this Agreement is to jointly  develop  genomic
        DNA-based  diagnostic  products (the  "Products") to detect the Targeted
        Traits in bovine animals in respect to meat  production or processing in
        the animal  production and meat  processing  industries with the goal of
        jointly  commercializing  such Products for sale,  following the Cargill
        Period of Exclusivity, to potential buyers in these industries initially
        in [****] and, ultimately [****].

8.2     NEQOTIATION OF AQREEMENT. Upon completion of Part 4 of the Work Plan and
        the making of the payment for Part 4 of the Work Plan, the Parties shall
        thereupon  and  thereafter  negotiate in good faith (with each other and
        perhaps  also  with  third  parties)  the  terms of a  definitive  Joint
        Commercialization  Agreement  regarding  the  development,  manufacture,
        marketing,  sales,  delivery,  and  distribution  of the Products to The
        Cargill  Entities and following the  expiration of the Cargill Period of
        Exclusivity,  to others. Unless this Agreement is sooner terminated, for
        at least [****] months after the  completion of Part 4 of the Work Plan,
        such  negotiations  shall  continue and neither Party may enter into any
        negotiations,  discussions,  or agreements  regarding  the  development,
        manufacture,  marketing,  sales,  delivery,  and  distribution  of  such
        Products with any Third Party, notwithstanding.

8.3     CORE  COMMERCIALIZATION  CONCEPTS.  Due to the  intrinsic  uncertainties
        associated  with  the  type of  research  project  contemplated  by this
        Agreement,  the Parties  desire to retain a degree of  flexibility  with
        respect   to  the   precise   terms   and   structure   that  the  Joint
        Commercialization Agreement may take.

                                       19
<PAGE>

                                  CONFIDENTIAL

        At the same time,  however,  the  Parties  desire to set forth below the
        general  commercialization  concepts  on which they have  reached  basic
        agreement  and around which they will conduct  their  negotiations  (the
        "Core Commercialization Concepts"):

        (a)     The  Parties  desire to pursue  joint  commercialization  of the
                Products only if such an effort is likely to achieve  acceptable
                returns.   The  Parties  will  jointly  develop  and  prepare  a
                five-year financial forecast (for the five-year period following
                expiration of the Cargill Period of  Exclusivity)  of the income
                statement  and balance  sheet for the  commercialization  of the
                Products.

        (b)     The  Parties  desire to pursue  joint  commercialization  of the
                Products only if the Products are technically effective and thus
                attractive   to  potential   buyers.   Presently,   the  Parties
                anticipate  proceeding  with  joint   commercialization  of  the
                Products only if the Products are  envisioned to cost to the end
                user, per test, is less than, per animal,  [****] of the [****].
                The Parties shall  formally  assess the  likelihood of exceeding
                such  thresholds  upon  the  conclusion  of Part 3 and  upon the
                conclusion of Part 4.

        (c)     The Parties,  after  reimbursing  MMI for the actual cost of the
                test  (which cost (i) shall be  determined  in  accordance  with
                generally  accepted  accounting  standards after a review by The
                Cargill  Entities of such cost and (ii) may include a reasonable
                apportionment  of the cost of any new or expanded  facility  for
                the  production of such tests and the provision of  test-related
                services),  will split net profits  and/or  losses  arising from
                commercialization  of the Products on an equal 50/50 basis.  MMI
                shall consult with The Cargill Entities prior to the purchase of
                a new facility or expansion of an existing facility in regard to
                the  production  of  tests  and the  provision  of  test-related
                services if MMI then intends to include an apportionment of such
                cost in the deemed "actual cost" of the test.

        (d)     The Parties will each  contribute  people and other resources to
                the joint  commercialization  effort at their direct costs.  For
                example,  MMI will produce and provide the DNA  collection  tool
                and the laboratory and/or diagnostic/analytical  services to the
                joint commercialization  effort at its direct cost (as such cost
                is calculated in accordance with Section 6.3).

        (e)     The Parties will use their joint  commercialization  vehicle not
                only for the Products,  but also for any other traits related to
                [****]  and/or [****] in meat  producing  bovines or relating to
                DNA-based  diagnostic  tools that the  Parties  may be  involved
                with.

                                       20
<PAGE>

                                  CONFIDENTIAL

        (f)     The Parties will target a price for the  Products  based upon at
                least thirty  percent (30%) of the "value added"  benefit to the
                purchaser   as   determined   during  the   Cargill   Period  of
                Exclusivity.

        (g)     Subsequent  to the  Cargill  Period  of  Exclusivity  (or if The
                Cargill  Entities,  with the agreement of MMI,  desire to exceed
                [****] samples during such Period,  shall pay the same price for
                the Products as would a Third Party (although the net revenue as
                of such sale to The Cargill  Entities would be split between The
                Cargill Entities and MMI).

        (h)     The  Parties  shall  assess  whether the  authorized  use of any
                diagnostic Product should be restricted initially to [****].

8.4     INABILITY TO REACH  AGREEMENT.  In the event that the Parties are unable
        to reach agreement on the terms of a Joint  Commercialization  Agreement
        for any reason  whatsoever within the time set forth in Section 8.2, the
        provisions  of Section  5.3.2 and  Section  8.5 shall  apply  unless the
        Parties then otherwise agree.

8.5     ROYALTIES  PAID TO OTHER JOINT IP PARTY.  In the event that both parties
        are permitted to make,  use,  sell, or sublicense the Joint IP to detect
        the Targeted  Traits in bovine animals in respect to meat  production or
        processing in accordance  with (a) Sections 5.3.2 and 8.4 or (b) Section
        7.4.1,  either Party so making,  using,  selling,  or sublicensing  such
        Joint IP in such  fashion  shall pay the other Party  (i.e.,  MMI to The
        Cargill  Entities  or The Cargill  Entities to MMI) a quarterly  royalty
        upon sales (for the  greater of the life of any patent upon any Joint IP
        or fifteen (15) years).  Such royalty shall be a percentage of net gross
        sales,  which shall be gross sales less the aggregate  cost of continued
        research and development (but not, in this respect,  exceeding more than
        one-half of gross sales),  marketing,  insurance,  and shipping (but not
        net of taxes), as follows:

        PERCENTAGE        CONDITION OR TIMING
        ----------        -------------------
          [****]%         If Part 3 never completed.

          [****]%         If Part 3, but no subsequent Part was completed.

          [****]%         If Part 4 was completed,  but the Parties  elected not
                          to proceed with feedlot  testing  under  Section 6 and
                          did  not   enter   into  a   Joint   Commercialization
                          Agreement.

          [****]%         If feedlot testing was undertaken under Section 6, but
                          the    Parties    did   not   enter   into   a   Joint
                          Commercialization Agreement.

                                       21
<PAGE>

                                  CONFIDENTIAL

         9         REPRESENTATIONS AND WARRANTIES AND GENERAL COVENANTS

9.1     Each Party represents and warrants to the other Party,  upon on the date
        upon which this Agreement is executed and upon the  commencement of each
        Part of the Work Plan, that:

        (a)     it is duly  organized and validly  existing and in good standing
                under the laws of the state of its  incorporation and it has the
                corporate  power and authority and the legal right to enter into
                this Agreement and to perform its obligations hereunder;

        (b)     the execution and delivery of this Agreement and the performance
                of  the   transactions   contemplated   hereby  have  been  duly
                authorized by all necessary  corporate actions of such Party and
                the person  executing this Agreement on behalf of each Party has
                been  duly  authorized  to  do  so by  all  requisite  corporate
                actions;

        (c)     the execution and delivery of this Agreement and the performance
                by such Party of any of its obligations  under this Agreement do
                not (i) conflict  with,  or constitute a breach or violation of,
                any other  contractual  obligation  to which it is a Party,  any
                judgment of any court or  governmental  body  applicable to such
                Party or its  properties  or,  to such  Party's  knowledge,  any
                statute,  decree,  order,  rule or  regulation  of any  court or
                governmental  agency  or body  applicable  to such  Party or its
                properties,  and (ii) with respect to the execution and delivery
                of this Agreement,  require any consent or approval of any Third
                Party;

        (d)     it is  aware  of no  action,  suit,  inquiry,  or  investigation
                contemplated  or instituted by any Third Party that questions or
                threatens the validity of this Agreement; and

        (e)     this  Agreement  is  legally  binding  upon its  execution  and,
                subject to the discretion of courts in awaiting equitable relief
                and  to  applicable  bankruptcy,   reorganization,   insolvency,
                moratorium, and similar laws, enforceable in accordance with its
                terms.

9.2     The Cargill Entities represent and warrant that they are entitled to use
        and  transfer  to MMI the  Samples,  data,  and/or  information  for the
        purpose(s) set forth in this Agreement.

9.3     Each Party shall (a) comply with all applicable laws,  regulations,  and
        guidelines  in  connection   with  that  Party's   performance   of  its
        obligations and exercise of its rights  pursuant to this Agreement,  (b)
        maintain  good  standing  under  the  laws  of  the  jurisdiction  of is
        incorporation,  and (c) not enter into any  contractual  obligation that
        would  conflict with or constitute a breach or violation of any material
        provision of this Agreement.

                                       22
<PAGE>

                                  CONFIDENTIAL

               10         DISCLAIMERS AND LIMITATION OF LIABILITY

10.1    NOTWITHSTANDING  SECTION 5.8,  NOTHING IN THIS AGREEMENT  (EXCEPT TO THE
        LIMITED  EXTENT  SET  FORTH IN  SECTION  9.2)  SHALL BE  CONSTRUED  AS A
        REPRESENTATION  MADE OR WARRANTY  GIVEN BY EITHER PARTY OR ITS SUPPLIERS
        THAT  THE USE OF ANY  INFORMATION,  DATA,  OR OTHER  MATERIALS  PROVIDED
        HEREUNDER WILL NOT INFRINGE ANY PATENT,  COPYRIGHT,  TRADEMARK, OR OTHER
        RIGHTS OF ANY THIRD PARTY.  THE  INFORMATION,  DATA, OR OTHER  MATERIALS
        PROVIDED BY EITHER PARTY HEREUNDER ARE PROVIDED "AS IS" WITHOUT WARRANTY
        OF ANY KIND  WHATSOEVER,  EXPRESS  OR  IMPLIED,  INCLUDING  THE  IMPLIED
        WARRANTIES  OF  MERCHANTABILITY  OR FITNESS  FOR A  PARTICULAR  PURPOSE.
        NEITHER  PARTY MAKES ANY WARRANTY THAT THE  DELIVERABLES  DO NOT CONTAIN
        ERRORS OR, IF APPLICABLE,  THAT ANY ASSEMBLED  ORGANISM DOES NOT CONTAIN
        GAPS.

10.2    IN NO EVENT SHALL  EITHER PARTY OR THEIR  AFFILIATES  BE LIABLE FOR LOST
        PROFITS, LOSS OF USE, LOSS OF BUSINESS,  BUSINESS INTERRUPTION,  LOSS OF
        DATA,  COST  OF  COVER  OR  ANY  INDIRECT,  SPECIAL,   CONSEQUENTIAL  OR
        INCIDENTAL  DAMAGES OF ANY NATURE  WHATSOEVER,  HOWEVER CAUSED AND UNDER
        ANY  THEORY OF  LIABILITY  WHETHER  BASED IN  CONTRACT,  WARRANTY,  TORT
        (INCLUDING WITHOUT LIMITATION, NEGLIGENCE), STRICT LIABILITY, STATUTORY,
        OR OTHERWISE,  ARISING OUT OF OR IN CONNECTION  WITH THIS AGREEMENT EVEN
        IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

10.3    THE  LIABILITY  OF THE  PARTIES,  THEIR  RESPECTIVE  AGENTS,  EMPLOYEES,
        SUBCONTRACTORS,  AND  SUPPLIERS  WITH  RESPECT  TO ANY  AND  ALL  SUITS,
        ACTIONS,  LEGAL  PROCEEDINGS,   CLAIMS,  DEMANDS,  DAMAGES,  COSTS,  AND
        EXPENSES  ARISING  OUT  OF  THE  PERFORMANCE  OR  NONPERFORMANCE  OF ANY
        OBLIGATIONS UNDER THIS AGREEMENT,  WHETHER BASED ON CONTRACT,  WARRANTY,
        TORT (INCLUDING,  WITHOUT  LIMITATION,  NEGLIGENCE),  STRICT  LIABILITY,
        STATUTORY, OR OTHERWISE,  SHALL BE LIMITED TO (a) DIRECT, ACTUAL DAMAGES
        INCURRED  AS A RESULT OF ITS  FAILURE  TO  PERFORM  ITS  OBLIGATIONS  AS
        REQUIRED BY THIS  AGREEMENT,  AND (b) EXCEPT IN RESPECT TO THE  PAYMENTS
        SET FORTH IN EXHIBIT C, SHALL NOT EXCEED IN THE AGGREGATE A SUM EQUAL TO
        TWO MILLION DOLLARS.

10.4    NOTWITHSTANDING  ANYTHING TO THE CONTRARY  CONTAINED HEREIN, THE PARTIES
        RECOGNIZE THAT ANY JOINT TECHNOLOGY  DISCOVERED,  CREATED,  OR DEVELOPED
        UNDER  THIS   AGREEMENT   MAY  BE  SUBJECT  TO  A  THIRD  PARTY'S  PRIOR
        INTELLECTUAL PROPERTY RIGHTS.

                                       23
<PAGE>

                                  CONFIDENTIAL

                              11         INDEMNITY

11.1    THE CARGILL ENTITIES INDEMNITY.  Subject to the limitations set forth in
        Section 10 above, The Cargill Entities shall indemnify, defend, and hold
        harmless MMI (including its officers, directors,  employees, and agents)
        from and against all personal or property losses, liabilities,  damages,
        and expenses  (including  reasonable  attorneys' fees and costs) arising
        (a) out of the falsehood or  inaccuracy  in any material  respect of any
        representation  or warranty or out of the breach or  non-fulfillment  of
        any material  covenant or agreement  of The Cargill  Entities  contained
        herein  or  contemplated  hereby;  (b) out of the  gross  negligence  or
        intentional  misconduct of The Cargill  Entities in connection  with the
        performance  of The  Cargill  Entities  of its  obligations  under  this
        Agreement;  and/or (c) out of The Cargill  Entities'  use of The Cargill
        Entities  Technology;  except to the extent  any such  loss,  liability,
        damage,  or expense  arises from the action or inaction of MMI.

11.2    MMI INDEMNITY. Subject to the limitations set forth in Section 10 above,
        MMI shall  indemnify,  defend,  and hold  harmless The Cargill  Entities
        (including  its  officers,  directors,  employees  and agents)  from and
        against all  personal  or property  losses,  liabilities,  damages,  and
        expenses  (including  reasonable  attorneys' fees and costs) arising (a)
        out of the  falsehood  or  inaccuracy  in any  material  respect  of any
        representation or warranty or out of the breach or nonfulfillment of any
        material  covenant or agreement of MMI contained  herein or contemplated
        hereby or (b) out of the gross  negligence or intentional  misconduct of
        MMI in connection  with the  performance of its  obligations  under this
        Agreement, and/or (c) out of the MMI's use of MMI Technology;  except to
        the extent any such loss,  liability,  damage or expense arises from the
        action or inaction of The Cargill Entities.

11.3    PROCEDURE.  The Indemnitee  shall promptly  notify the Indemnitor of any
        loss,  liability,  damage,  expense,  claim,  demand,  action,  or other
        proceeding  in  respect  of which the  Indemnitee  intends to claim such
        indemnification,  and the Indemnitor shall have the right to participate
        in, and, to the extent the Indemnitor so desires, jointly with any other
        Indemnitor similarly noticed, to assume the defense thereof with counsel
        selected  by  the  Indemnitor  and   reasonably   satisfactory   to  the
        Indemnitee;  provided,  however, that an Indemnitee shall have the right
        to retain its own counsel,  with the fees and expenses to be paid by the
        Indemnitee, if representation of such Indemnitee by the counsel retained
        by the  Indemnitor  would be  inappropriate  due to actual or  potential
        differing   interests  between  such  Indemnitee  and  any  other  Party
        represented by such counsel in such proceedings. The indemnity agreement
        in this Section 11 shall not apply to amounts paid in  settlement of any
        loss,  liability,  damage,  expense,  claim,  demand,  action,  or other
        proceeding if such settlement  shall be effected  without the consent of
        the Indemnitor,  which consent shall not be unreasonably  withheld.  The
        failure to deliver  notice to the  Indemnitor  within a reasonable  time
        after the

                                       24
<PAGE>

                                  CONFIDENTIAL

        commencement of any such action, if prejudicial to its ability to defend
        such action,  shall  relieve  such  Indemnitor  of any  liability to the
        Indemnitee under this Section 11 to the extent  Indemnitor is prejudiced
        by Indemnitee's delay, but the omission of such notice to the Indemnitor
        will not relieve it of any liability  that it may have to the Indemnitee
        otherwise  than under this Section 11. The Indemnitor may not settle the
        action or  otherwise  consent to an adverse  judgment  in such action or
        other  proceeding that effects the rights or interests of the Indemnitee
        without the express written  consent of the  Indemnitee.  The Indemnitee
        under this Section 11, and its  employees  and agents,  shall  cooperate
        fully  with  the  Indemnitor  and  its  legal   representatives  in  the
        investigation  of  any  action,  claim  or  liability  covered  by  this
        indemnification.

11.4    INSURANCE.   Each  Party  shall  maintain,   through  self-insurance  or
        commercially  placed insurance,  adequate coverage for the tort-related,
        non-contract-based  indemnification  obligations  set forth  herein  and
        shall  provide  competent  proof  of such  insurance  within  three  (3)
        business days after receipt of a written request from the other Party.

                          12         GENERAL PROVISIONS

12.1    NO PARTNERSHIP. Nothing in this Agreement is intended or shall be deemed
        to constitute partnership,  agency, distributorship,  employer-employee,
        or joint venture  relationship  between The Cargill Entities and MMI. No
        Party shall incur any debts or make any commitments for the other.

12.2    ASSIGNMENTS. Neither Party shall assign any of its rights or obligations
        hereunder  in whole  or in part,  except  (notwithstanding  anything  in
        Section  5.3.1,  Section  6.2, or Section 8.2 to the  contrary):  (a) as
        incident to the merger, consolidation, reorganization, or acquisition of
        stock or assets or a similar transaction  affecting all or substantially
        all of the assets or voting  control of the assigning  Party;  or (b) to
        any directly or  indirectly  wholly-owned  subsidiary  if the  assigning
        Party remains liable and  responsible for the performance and observance
        of all of the  subsidiary's  duties and  obligations  contained  in this
        Agreement;  or (c) in any  conveyance of assets that are material to the
        performance of any obligation  contained in this Agreement,  or (d) with
        the consent of the other  Party,  such  consent  not to be  unreasonably
        withheld or delayed. Upon any such assignment,  the assigning Party, the
        other Party, and the permitted  assignee shall enter into an appropriate
        confirmatory agreement. Notwithstanding anything in this Section 12.2 to
        the contrary,  The Cargill  Entities,  if they are the assigning  Party,
        shall give MMI reasonable  advance  notice if the intended  assignee has
        any  operations  in  poultry,  swine,  or  other  non-bovine  livestock,
        whereupon  appropriate "fire wall"  confidentiality  restrictions  shall
        first be established within the assignee entity. This Agreement shall be
        binding,  upon the successors and permitted assigns of the Parties,  and
        the name of a Party  appearing  herein  shall be deemed to  include  the
        names of such Party's  successors  and  permitted  assigns to the extent
        necessary to carry out the intent

                                       25
<PAGE>

                                  CONFIDENTIAL

        of this Agreement. Any assignment not in accordance with the above shall
        be void.

12.3    FURTHER ACTIONS. The Parties agree to promptly execute, acknowledge, and
        deliver such further instruments,  and to do all such other acts, as may
        be  necessary  or  appropriate  in order to carry out the  purposes  and
        intent of this Agreement.

12.4    NO TRADEMARK RIGHTS. Except as otherwise provided herein or agreed to in
        advance in writing,  no right,  express or  implied,  is granted by this
        Agreement to use in any manner the trade names and trademarks "Cargill,"
        "Excel,"  "Caprock,"  "MetaMorphix,"  "Celera,"  "Celera  Genomics," "PE
        Corporation  (NY)," "Applera," or any other trade name or trademark of a
        Party, its Affiliates,  or the names of any employees  thereof,  for any
        purpose other than the Parties' internal purposes and uses.

12.5    ENTIRE AGREEMENT OF THE PARTIES;  AMENDMENTS. This Agreement,  including
        its  Exhibits,  constitutes  and contains the entire  understanding  and
        agreement  of the Parties and cancels and  supersedes  any and all prior
        negotiations,  correspondence,   representations,   understandings,  and
        agreements,  whether verbal or written,  between the Parties  respecting
        the subject  matter  hereof.  In case of any  discrepancies  between the
        terms  incorporated  from the  Exhibits  and the  terms of the  sections
        herein,   the  terms  of  the  sections   shall   prevail.   No  waiver,
        modification,  or amendment of any provision of this  Agreement  (and/or
        the  Exhibits)  shall be valid or  effective  unless made in writing and
        signed by a duly authorized representative of each Party. The failure or
        delay  of  either  Party  in  enforcing  any of its  rights  under  this
        Agreement  shall not be deemed a continuing  waiver or a modification by
        such Party of such right.

12.6    SEVERABILITY.  In the  event any that one or more of the  provisions  of
        this  Agreement  should for any reason be held by any court or authority
        having jurisdiction over this Agreement.  or either of the Parties to be
        invalid,  illegal, or unenforceable,  such provision or provisions shall
        be validly  reformed to as nearly as possible  approximate the intent of
        the Parties and, if unreformable, shall be divisible and deleted in such
        jurisdiction; elsewhere, this Agreement shall not be affected so long as
        the Parties are still able to realize the principal  benefits  bargained
        for in this Agreement.

12.7    HEADINGS.  The headings to this Agreement are for convenience  only, and
        are to be of no force or effect in construing or interpreting any of the
        provisions of this Agreement.

12.8    GOVERNING  LAW.   This Agreement shall be governed by and interpreted in
        accordance with the laws of the State of Delaware,  without reference to
        the conflict of law principles  thereof and without regard to the United
        Nations Convention on the International Sale of Goods.

                                       26
<PAGE>

                                  CONFIDENTIAL

12.9    NOTICES AND DELIVERIES.  Any notice,  request,  delivery,  approval,  or
        consent  required or permitted to be given under this Agreement shall be
        in writing and shall be delivered  personally (against a signed receipt)
        or by a nationally  recognized  overnight  courier,  costs prepaid,  and
        shall be deemed to have been duly  given  when so  delivered  in person,
        with  receipt  confirmed,  or one (1)  business  day  after  the date of
        deposit with such  nationally  recognized  overnight  courier.  All such
        notices,   requests,   deliveries,   approvals,   consents,   or   other
        communications  shall be  addressed  to the  respective  Parties  at the
        addresses  set forth  below,  or to such  other  address  as a Party may
        designate to the other Party in accordance herewith.

        12.9.1  If to MMI, addressed to:

                        MetaMorphix, Inc.
                        8510A Corridor Road
                        Savage, Maryland 20763
                        Attn: Edwin C. Quattlebaum, Ph.D., President and CEO

                with a copy to:

                        Shapiro Sher & Guinot
                        36 S. Charles Street, Suite 2000
                        Baltimore, Maryland 21201 Attn:
                        William E. Carlson, Esq.

        12.9.2  If to The Cargill Entities, addressed to:

                        Excel Corporation
                        151 North Main Street
                        Wichita, Kansas 67202
                        Attn: Ken Bull

                with a copy to:

                        Cargill, Incorporated
                        Law Department
                        15407 McGinty Road West
                        Wayzata, Minnesota 55391
                        Attn: Paul B. Savereide, Ph.D., Esq.

        Notices of  meetings  of the  Steering  Committee  shall be given to its
        members at such  addresses  and in such  manner as may be,  from time to
        time, requested by its members or determined by the Committee.

                                       27
<PAGE>

                                  CONFIDENTIAL

12.10   COUNTERPARTS.   This   Agreement   may  be  executed  in  two  or.  more
        counterparts,  each of which  shall be  deemed an  original,  but all of
        which together shall constitute one and the same instrument.

12.11   FORCE  MAJEURE.  If the  performance  of any part of this  Agreement  by
        either  Party,  or of any  obligation  under  this  Agreement,  shall be
        prevented,  restricted,  interfered  with,  or  delayed by reason of any
        cause  beyond the  reasonable  control of the Party  liable to  perform,
        unless conclusive evidence to the contrary shall be provided,  the Party
        so affected  shall,  upon giving written  notice to the other Party,  be
        excused  from  such  performance  to  the  extent  of  such  prevention,
        restriction,  interference,  or delay,  provided that the affected Party
        shall use its  commercially  reasonable  efforts to avoid or remove such
        causes of non-performance and shall continue performance with the utmost
        dispatch  whenever  such  causes are  removed.  When such  circumstances
        arise, the Parties shall discuss what, if any, modification of the terms
        of this  Agreement  may be required  in order to arrive at an  equitable
        solution.

12.12   DISPUTE  RESOLUTION.  MMI and The Cargill  Entities shall deal with each
        other in good  faith.  In the event that a dispute  arises  between  the
        Parties  concerning,  or in any way  relating  to, this  Agreement,  the
        Parties  shall  undertake  good faith  efforts to amicably  resolve such
        dispute.

        12.12.1 EXECUTIVE OFFICERS.  In the event that the Parties are unable to
                resolve  any such  dispute,  the matter  shall be  referred  for
                further review and resolution to MMI's Chief Executive  Officer,
                or  another  designated   representative  of  MMI,  and  to  the
                President   of  Excel   Corporation,   or   another   designated
                representative of The Cargill Entities, who will attempt in good
                faith and reasonable diligence to resolve the dispute.

        12.12.2 MEDIATION.  If the dispute is not  resolved  within  thirty (30)
                days after referral under Section 12.12.1, or such other time as
                mutually  agreed  upon in writing by the  Parties,  the  Parties
                shall  submit  the  matter  to   non-binding   mediation  to  be
                administered by the American  Arbitration  Association under its
                Commercial  Mediation  Rules in effect at the time of mediation.
                The  Party  desiring  such   mediation   shall  initiate  it  in
                accordance with the Commercial Mediation Rules. Upon delivery of
                the mediation request,  the Parties shall endeavor in good faith
                to select a neutral mediator who is acceptable to each Party. If
                the  Parties  have not  selected a mutually  acceptable  neutral
                mediator  within five (5)  business  days after  delivery of the
                mediation  request,  they shall notify the American  Arbitration
                Association and request the American Arbitration  Association to
                appoint a  mediator  in  accordance  with the  Mediation  Rules.
                Unless  otherwise  agreed  upon by the  Parties,  all  mediation
                sessions  shall  be  held  in  Chicago,  Illinois  as a  neutral
                location or, if several  sessions are to be held, in alternative
                sessions in Denver,  Colorado and in  Baltimore,  Maryland.  The
                Parties shall

                                       28
<PAGE>

                                  CONFIDENTIAL

                endeavor  in good  faith to  resolve  the  dispute  through  the
                mediation process contemplated by this Section and neither Party
                shall be entitled  unilaterally to terminate the mediation prior
                to thirty (30) days after the appointment of a mediator.

       12.12.3  BINDING  ARBITRATION.  If the  dispute is not  resolved  through
                mediation  under Section  12.12.2,  the Parties shall submit the
                matter to binding arbitration to be administered by the American
                Arbitration  Association under its Commercial Rules in effect at
                the time of  arbitration.  The Party  desiring such  arbitration
                shall initiate it in accordance with the Commercial  Arbitration
                Rules except as provided below.  The arbitration  shall be heard
                and determined by a panel of three  arbitrators (at least one of
                which shall have considerable  agribusiness experience, at least
                one of which shall have considerable genomic experience,  and at
                least  one of whom  shall  be a  practicing  lawyer  or  retired
                judge).  The arbitrators shall be selected by the Parties from a
                proposed  list of  possible  arbitrators  provided by the AAA in
                accordance  with a process  determined  by the AAA.  The Parties
                shall be afforded  reasonable  opportunity for discovery and the
                Federal Rules of Discovery shall apply.  Unless otherwise agreed
                upon by the Parties,  all arbitration  sessions shall be held in
                alternative   sessions  in  Denver,   Colorado  and   Baltimore,
                Maryland.  The  decision of the  arbitrators  shall be final and
                binding upon Parties.  Notwithstanding  anything in this Section
                12.12.3 to the contrary,  such arbitration  shall not proceed or
                be binding if there is either any third-party  claimant involved
                in  the  specific  dispute  proposed  to be  arbitrated  or  any
                necessary third-party defendant or co-defendant.

       12.12.4  INJUNCTION.  Notwithstanding  anything in this Section  12.12 to
                the contrary,  an aggrieved  Party, to the extent that it may be
                otherwise be entitled under applicable law governing injunctions
                and  equitable  relief,  may seek and  shall be  entitled  to an
                injunction  prohibiting  any material breach (or other equitable
                relief)  in  regard  to  Article  4 or  Article  5. The  Parties
                recognize the importance of the  confidentiality and publication
                provisions of Article 4 and intellectual  property provisions of
                Article 5 and  acknowledge  that an aggrieved Party could suffer
                irreparable  harm  as a  result  of a  material  breach  of such
                provisions.

       12.12.5  CONFIDENTIALITY.  The  Parties  hereby  mutually  agree that the
                existence,  terms, and content of any dispute resolution entered
                into pursuant to this  Agreement,  as well as all information or
                documents  relating  thereto,  shall be maintained in confidence
                and not be given,  shown,  disclosed  to, or discussed  with any
                Third  Party  except:  (a) by prior  written  agreement  of both
                Parties;  (b) during any legal proceeding to protect or secure a
                Party's  rights under such dispute  resolution;  (c) counsel and
                accountants who shall agree to maintain its confidentiality;

                                       29
<PAGE>

                                     CONFIDENTIAL

                (d) to the extent required by applicable reporting requirements;
                and (e) upon compulsory legal process.

        IN WITNESS WHEREOF,  the Parties have caused this Joint  Development and
Joint  Marketing  Agreement to be executed by their  respective  duly authorized
officers.

METAMORPHIX, INC.                       CARGILL, INCORPORATED

By: /s/ Edwin C. Quattlebaum            By: /s/ William Buckner
   ---------------------------------       ---------------------------------
       Edwin C. Quattlebaum, Ph.D             Name:
       President and CEO                      Title

       Date: May ,2002                      Date: May 6, 2002

_____________                           EXCEL CORPORATION

                                        By: /s/ Kenneth Bull
                                           ---------------------------------
                                              Name:
                                              Title:

                                              Date:  May 6, 2002

                                       30
<PAGE>

                                  CONFIDENTIAL

                                    EXHIBIT A

                                   DEFINITIONS

1.      "Affiliates"  shall mean any corporation,  firm,  partnership,  or other
        legal entity that, directly or indirectly,  controls,  is controlled by,
        or is under common  control with any of the Parties.  A  corporation  or
        other entity shall be regarded as in control of another  corporation  or
        entity, if: (a) in the case of corporate entities it owns or directly or
        indirectly  controls more than fifty  percent  (50%) of the  outstanding
        voting stock or other  ownership  interest of the other  corporation  or
        entity, or if it possesses, directly or indirectly, the power to manage,
        direct or cause the  direction  of the  management  and  policies of the
        corporation  or other  entity  or the  power to elect or  appoint  fifty
        percent  (50%)  or  more of the  members  of the  governing  body of the
        corporation  or  other  entity;  and (b) in the  case  of  non-corporate
        entities,  direct or indirect  ownership of at least fifty percent (50%)
        interest  with the power to direct the  management  and policies of such
        non-corporate entities.

2.      "Annotation Information" shall mean the information derived by analyzing
        the DNA Sequence  Information to identify  features  associated with the
        sequences,  and the functional information resulting from such analysis,
        including,  but not  limited  to,  homology  information,  DNA  sequence
        cluster and assembly identifiers, gene predictions, orthologs and marker
        locations on chromosome maps

3.      "Celera" shall mean PE  Corporation  (NY),  through its Celera  Genomics
        Group.

4.      "Complete Delivery" shall mean MMI's delivery to The Cargill Entities of
        all of the Deliverables set forth in the Work Plan.

5.      "Confidentiality    Agreements"    shall   mean,    collectively,    the
        non-disclosure agreement executed by The Cargill Entities and Celera and
        dated April 18,  2001 (and to which  Celera has  assigned  its rights to
        MMI) and the  non-disclosure  agreement executed by The Cargill Entities
        and MMI and dated November 29, 2001.

6.      "Confidential  Information"  shall mean the  existence and terms of this
        Agreement,  the  Deliverables,   Records,   business  information,   and
        technical  information  relating to The Cargill Entities  Material,  the
        Datasets,  The Cargill  Entities  Technology,  MMI Technology,  or other
        information  belonging  to  the  disclosing  Party,   including,   where
        appropriate  and  without   limitation,   any  associated   information,
        business,  financial  and  scientific  data,  DNA sequence  information,
        annotation  information,   invention  disclosures,  patent  disclosures,
        patent  applications,   structures,   models,   techniques,   processes,
        compositions,   compounds,   biological  samples,   and  the  like,  and
        bioinformatics methods, hardware configurations and software (regardless
        of its stage of development), and the like.

                                       31
<PAGE>

                                  CONFIDENTIAL

7.      "Dataset" shall mean a compilation of the information and data resulting
        from MMI's activities under the Work Plan.

8.      "Default"  shall mean a breach or default  of a material  obligation  of
        this Agreement and/or a false  representation or warranty made by either
        party under this Agreement.

9.      "Deliverable" shall mean any of the Datasets, information,  reports, and
        other  items in whole or in part,  required to be provided by MMI to The
        Cargill  Entities  under the Work  Plan set  forth in  Exhibit B of this
        Agreement.

10.     "DNA  Sequence   Information"  shall  mean  the  respective   consensus,
        nonredundant nucleotide sequences for the Samples.

11.     "Genotype"   shall  mean  the  specific  nucleic  acid  sequence  of  an
        individual found at a specific location in the genome.

12.     "Genotyping"  shall mean the analysis of nucleic acid sequence variation
        at a specific location in the genome.

13.     "Indemnitee"  shall mean the Party that intends to seek  compensation or
        protection pursuant to this Agreement.

14.     "Indemnitor"  shall  mean  the  Party  from  whom the  Indemnitee  seeks
        compensation or protection.

15.     "Joint Commercialization  Agreement" shall mean an agreement between the
        Parties regarding the sale,  exploitation,  and commercialization of any
        products  or  services  relating  to  any  trait-specific   assay  that,
        individually or in combination, detects the Targeted Traits.

16.     "Joint  Intellectual  Property" or "Joint IP" shall mean any technology,
        data, information,  inventions,  know-how,  trade secrets, and the like,
        whether patentable or not, that are conceived,  identified,  discovered,
        developed,  or invented by the Parties or any of them pursuant to any of
        the  activities  conducted  pursuant  to the Work  Plan.  Joint IP shall
        include all the Deliverables  described in the Work Plan,  including but
        not limited to the Validated SNP Set (as defined in the Work Plan),  the
        Associated  SNP Sets,  the  Diagnostic SNP Sets for each of the Targeted
        Traits, all Datasets (subject to Section 7.8), all information contained
        in any reports  issued by MMI under the Work Plan,  the results and data
        of  the   association   studies   (subject  to  Section  7.8),  and  any
        trait-specific  assay that  individually or in combination,  detects the
        Targeted Traits.

17.     "MMI Technology" shall mean assay technology and all data,  information,
        inventions,  know-how,  technology,  trade secrets and the like, whether
        patentable  or not,  that  are (a)  conceived,  identified,  discovered,
        developed, or invented in

                                       32
<PAGE>

                                  CONFIDENTIAL

        whole or part-by or on behalf of MMI independent of The Cargill Entities
        and  independent  of The Cargill  Entities  material  and/or The Cargill
        Entities Technology,  including the Putative SNP Set and/or (b) acquired
        or licensed by MMI from Third Parties.

18.     "Payment  Schedule"  shall mean the payment terms for this  Agreement as
        set forth in Exhibit C and all amendments thereto.

19.     "Publication"  shall  mean any  information  or data  that  The  Cargill
        Entities seeks to disclose  electronically,  in writing or verbally,  or
        make publicly  available through any means,  including,  but not limited
        to, written document,  abstract,  poster, chart, slide presentation,  or
        article.

20.     "Putative  SNP Set" shall mean a set of at least  100,000  putative SNPs
        that  cover the bovine  genome.  and have  known,  unique  locations  on
        Celera's human genome (to which MMI has access by a license agreement).

21.     "Samples"  shall mean the blood samples from 3000 head of bovine animals
        used for meat  production  or  processing  to be provided by The Cargill
        Entities  under Part 2 of the Work Plan, the blood samples from 500 head
        of bovine animals used for meat  production or processing to be provided
        by The  Cargill  Entities  under  Part 4 of the  Work  Plan,  and  other
        biological  material that The Cargill  Entities supply to MMI. under the
        Work Plan.

22.     "Targeted Traits" shall mean the traits of [****] and [****].

23.     "Term" shall mean the period of time from the Effective Date through the
        later of the date on which MMI provides Complete Delivery to The Cargill
        Entities-or The Cargill Entities pays to MMI the final payment due under
        Section  3  (Payments)  or the  Agreement  is  otherwise  terminated  as
        provided for in this Agreement.

24.     "The Cargill Entities Material" shall mean the Samples, phenotypic data,
        and  other  information  required  to be or  otherwise  provided  by The
        Cargill Entities to MMI under the Work Plan.

25.     "The Cargill Entities  Technology" shall mean all data, including bovine
        animals used for meat  production or processing  phenotype data supplied
        by The Cargill Entities, information,  inventions, know-how, technology,
        trade  secrets,  and the like  including  the  Samples  and The  Cargill
        Entities  Material,  whether  patentable  or not,  that  are  conceived,
        identified, discovered, developed, or invented in whole or part by or on
        behalf of The Cargill Entities independent of MMI.

26.     "Third Party" shall mean any  individual,  partnership,  joint  venture,
        corporation,  trust, estate, unincorporated organization,  government or
        any department or

                                       33
<PAGE>

                                  CONFIDENTIAL

        agency  thereof,  or any other  entity  other than either of The Cargill
        Entities or MMI or any Affiliates of the Parties.

27.     Work  Plan"  shall  mean the  description  of the plan  under  which the
        Parties will fulfill their  obligations  under this Agreement as set out
        in Exhibit B, and any amendments thereto.

                                       34
<PAGE>

                                  CONFIDENTIAL

                                    EXHIBIT B
                                    WORK PLAN

                                    SNP MAPS

COMPLETED PART -- SNP MAP DEVELOPMENT
-------------------------------------

Completed by Celera Genomics,  licensor to MetaMorphix under a Livestock License
Agreement.

Cost to Celera Genomics: [****] dollars.

WORK PLAN

    o   [****] has constructed [****] from [****] breeds of cattle ([****]). The
        constructed [****] are a mixture of [****] ([****]),[****]  ([****]) and
        [****] ([****])[****] suitable for [****].

    o   Using [****] from [****] ([****]) of the [****], and [****]) the [****],
        using a [****] approach,  to a depth of [****] sufficient to generate at
        least [****] ([****])[****].

    o   Fragments  from the [****] of the [****] were compared and [****] to the
        [****] using a [****].

    o   At least [****] were  discovered  using [****].  This process  discovers
        [****], using [****] from the [****].

    o   These [****] were [****], to the [****].  They have been analyzed [****]
        using [****].

OUTCOME AND CELERA INPUT

    o   A set of at least [****]  putative SNPs that cover the bovine genome and
        have known,  unique  locations  on Celera's  [****] (the  "Putative  SNP
        Set").

MMI RIGHTS AND ACCESS

    o   Celera  has  licensed  access  to its  bovine  SNP maps,  database,  and
        technology to MetaMorphix.

PART I -- SNP MAP VALIDATION
----------------------------

Anticipated Start Date:                 May 10, [****]
Anticipated Completion Date:            December 1, [****]
Cost:                                   Four million three hundred thousand
                                        ($4,300,000) dollars

WORK PLAN

    o   MMI will  select up to [****] from the [****] for  validation.  Based on
        experience  in other  species,  MMl's  selection  criteria  will include
        [****],[****]  ([****]  and  [****]),  and the  likelihood  that MMI can
        predict if a [****] and [****].

    o   MMI will analyze the [****] as follows:

        (i)     a  representative  animal  from  each of the  following  [****],
                namely,  [****] and [****], will be used to [****] and [****] of
                each [****];

        (ii)    for those  [****] in the  representative  animal of [****],  MMI
                will [****] an  additional  [****] from each of these  [****] to
                determine the [****] of the [****] and [****].

                                       35
<PAGE>

    o   MMI elect a set of at least [****] from the [****] analyzed as described
        in this section of the Work Plan (the "Validated SNP Set") such that the
        selected SNPs  ("Validated  SNPs") have the best possible  [****] to the
        [****].

DELIVERABLE

    o   The Validated SNP Set.

    o   A report  detailing the Validated SNP Set including SNP  identification,
        [****]  location on [****] (if known),  and [****] in each breed  tested
        above.

        MMI may  maintain  the  confidentiality  of the SNP primer pairs and SNP
        amplicon sequence, i.e., marker names may remain anonymous in accordance
        with  Section  5.3.4.  In  accordance  with Section  5.3.4,  The Cargill
        Entities  may inspect and assess the SNP primer  pairs and SNP  amplicon
        sequence  to assist The  Cargill  Entities  in its  determination  under
        Section 3.3.  Such  inspection  and  assessment  shall not result in the
        disclosure  of specific  primer  pair and  sequence  information  to The
        Cargill Entities.

ACTION ITEM

    o   Steering  Committee to make  recommendations to the Parties to determine
        whether to continue or amend the Work Plan.  A  recommendation  shall be
        given to continue into Part 2 if the Deliverables are acceptable.

                                ASSOCIATION STUDY

ASSUMPTIONS
-----------

The plan for the  association  study is based on certain  assumptions,  which to
MMl's best knowledge will yield the expected outcomes,  but is subject to change
as new knowledge is acquired in the process.  MMI has yet to determine the final
genotyping  strategy to be used for the association  study.  MMI will choose the
strategy that delivers the most information the most efficiently.  In any event,
MMI  will  not  attempt  more  than  [****]  ([****])  genotypes  as part of the
association  study. The total number of genotyping  reactions will depend upon a
number of technical factors that will become evident as the research progresses.
These technical factors include, but are not limited to:

        (i)     number of [****];

        (ii)    the potential of [****] versus [****];

        (iii)   the  [****]  in  [****] of the  [****]  of the  [****],  and the
                appropriate number of animals in these [****];

        (iv)    the number of animals with [****];  and

        (v)     the number of [****] in the [****].

The following plan represents MMl's reasonable  estimate of the work required to
reach the  program's  objectives,  but is  subject  to change  depending  on the
results  of  previous  steps,  the  performance  and  practicability  of the SNP
detection system concept, and changes in the technology.

                                       36
<PAGE>

PART 2 -- ASSOCIATION STUDY -- PHASE ONE
----------------------------------------
Anticipated Start Date:                 January 1, [****]
Anticipated Completion Date:            December 1, [****]
Cost:                                   Four million four hundred thousand
                                        ($4,400,000) dollars

THE CARGILL ENTITIES INPUTS

    o   Twenty  milliliters  (20ml)  blood  samples in EDTA tubes  (purple  top)
        collected  from [****] to be delivered to MMI no later than  November 1,
        [****].

    o   [****] from each of the [****]  animals as follows,  to be  delivered to
        MMI no later than November 1, [****] in accordance with protocols (e.g.,
        refrigeration) reasonably established by MMI.

        [****]
        [****] would be assigned an [****] and have an [****] upon  entering the
        study.  Two  additional  [****]  will be recorded  when the [****].  The
        [****]  collected  from the [****] would include any  information  known
        about the [****] to their  [****]  ([****],  etc.) and the [****]  group
        would be  recorded.  Any  [****]  would be noted in the  record as well.
        [****] would be acquired at some time period prior to slaughter.

        [****] and [****]
        of [****], etc

        [****]
        [****] and any [****] recorded would enter
         the [****].  All information  [****] at the [****] would be included as
        follows.

        [****]
        [****]
        [****] recorded on [****] and [****] according to [****].

WORK PLAN

    o   MMI  will  determine  which  [****]  from  the  [****]  will  be used in
        Association  Study -- Phase Two. This  determination may be accomplished
        in one of two ways:  (i) by  analyzing  [****],  or (ii) by [****].  The
        success  of a [****]  depends  on the  [****]  of the  [****].  MMI will
        determine  the [****] of the  [****]  before  [****]  whether to use the
        [****]. In either approach, the number of [****] that must be [****] can
        be  determined  [****] the [****] are  [****].  This  number is based on
        [****] and the [****]. The two [****] are described below:

            o   In the [****],  MMI will  [****] no less than  [****]  using the
                [****]. MMI will create a minimum of [****] will be comprised of
                [****] least one of the [****] will be comprised of animals from
                the [****]  and  [****]  will be  comprised  of [****]  from the
                [****] of the [****] ([****]).

            o   In the  [****],  MMI will  [****] that would have been [****] in
                the [****], had the [****] been chosen, with the [****]. Animals
                that would have been  [****] in more than  [****]  (that is, the
                [****] for more than [****]) will be [****] only.

    o   MMI will record any [****]. For each [****],  based on these [****], MMI
        will identify a

                                       37
<PAGE>

        [****] from the [****] that show [****] of the [****] in the [****] (the
        "[****]").

DELIVERABLE

    o   MMI will screen [****] ([****])  Validated SNPs per thirty (30) days and
        deliver to The Cargill  Entities,  after the end of each such period,  a
        report listing all tested SNPs, SNP genotypes of genotyped animals,  and
        association test statistics.

ACTION ITEM

    o   Steering  Committee to make  recommendations to the Parties to determine
        whether to continue or amend the Work Plan.

PART 3 -- ASSOCIATION STUDY -- PHASE TWO
----------------------------------------

Anticipated Start Date:                 January 1, [****]
Anticipated Completion Date:            March 1, [****]
Cost:                                   One million one hundred thousand
                                        ($1,100,000) dollars

MMI INPUT:

    o   As a result of  Association  Study -- Phase One, MMI will have  selected
        the Reduced SNP Set for use in Association Study -- Phase Two

WORK PLAN

    o   Depending upon the strategy  selected in the Association  Study -- Phase
        One:

        o   If the [****] has been selected in  Association  Study -- Phase One,
            all [****] will be [****] with the [****].

        o   [****]  were  [****] to [****] the  Association  Study -- Phase One,
            then the [****] from the Phase One Association  Study will be [****]
            with the [****].

    o   MMI will  record any [****]  and  [****] in the  [****],  and [****] the
        [****] of the [****] on the [****]  contributed by [****] for which that
        [****] is a [****].

    o   MMI will create a table  identifying  [****] with the [****]  ("[****]")
        resulting in a [****] with each of the [****] (an "[****]").

DELIVERABLES

    o   The Associated SNP Sets.

    o   A report  listing  all  tested  SNPs,  SNP  genotypes  of all  genotyped
        animals, association test statistics and an [****] for the [****] of the
        [****] on the [****]  contributed by the [****] for which that [****] is
        a [****].  The report need not contain such information as is maintained
        as confidential in accordance with Section 5.3.4.

ANALYSIS OF ASSOCIATION STUDY
-----------------------------

Under the  guidance of the  Steering  Committee,  the Parties  will  analyze the
[****] and [****] data to determine  whether the Associated SNP Sets can lead to
acceptable  diagnostic  SNPs. The criteria will include  whether the anticipated
SNP-based  diagnostic test is likely to detect [****] that [****] in each of the
Targeted Traits. The Parties will use the [****] with which all the animals used
in the study fall into [****]  based on their  [****] to [****] the [****] as to
whether  or not they are  [****]  for  [****]  that  [****]  the [****] for each
[****], as well as all [****] of the

                                       38
<PAGE>

[****]. The Parties will analyze genetic  relationships among all SNP markers to
determine  if SNP  markers  for  alleles  that  [****] to [****]  for [****] the
phenotype for the other Targeted Traits.

The Parties  understand and acknowledge  that to create  significant  value, the
alleles  detected by diagnostic  SNP markers  should account for a [****] of the
[****] for each of the [****]; however, the Steering Committee's  recommendation
regarding  continuing  the  program  shall  be based  on its  assessment  of the
potential value that can be created by implementing an SNP-based diagnostic test
for a Targeted  Trait.  Specifically,  the Steering  Committee  shall assess the
probably "value added" benefit of the diagnostic SNP marker Product and the cost
per test.

ACTION ITEM

    o   Steering  Committee to make  recommendations to the Parties to determine
        whether to continue or amend the Work Plan. The recommendation  shall be
        given to continue  into Part 4 if it can be reasonably  envisioned  that
        the Product  will (1)  produce  more than [****]  dollars  ($[****])  in
        "[****]" [****] and (2) [****] of the [****].

                               DIAGNOSTIC PRODUCTS

PART 4 -- DEVELOPMENT AND VALIDATION OF DIAGNOSTIC PRODUCTS
-----------------------------------------------------------

Anticipated Start Date:                 April 1, [****]
Anticipated Completion Date:            June 1, [****]
Cost:                                   Four hundred thousand ($400,000) dollars

THE CARGILL ENTITIES INPUTS

    o   One (1) blood samples in an EDTA tube (purple top) with a minimum of ten
        (10) ml of blood will be collected from [****] ([****]) for which [****]
        have been (or will be)  collected  to be delivered to MMI not later than
        May 15, [****]. The phenotypes will not be delivered to MMI.

WORK PLAN

    o   If  necessary  to  create a  [****]  for  each of the  [****],  MMI will
        identify [****] from the [****] close to the [****] of the [****].

    o   MMI will determine which of these [****] to the [****] with [****].

    o   MMI will  select  [****] that are [****] for the [****] of the [****] to
        comprise [****] which can be used to [****] (a "[****]").

    o   MMI will validate these [****]  ([****])  [****] supplied by [****] that
        were not  [****] in the  either  the  Association  Study -- Phase One or
        Association Study -- Phase Two.

DELIVERABLES

    o   Diagnostic SNP Sets for each of the Targeted Traits.

    o   A report  listing the  genotypes of each of the [****] and the [****] of
        the [****] used in the validation study

                                       39
<PAGE>

EXHIBIT C
MILESTONES AND PAYMENTS

PART I -- SNP MAP VALIDATION
----------------------------

Anticipated Start Date:                 May 10, [****]
Anticipated Completion Date:            December 1, [****]
Cost:                                   Four million three hundred thousand
                                        ($4,300,000) dollars

By December 1, [****], MMI will deliver the Validated SNP Set and the report set
forth in Part I of the Work Plan detailing the Validated SNP.

PART 2 -- ASSOCIATION STUDY -- PHASE ONE
----------------------------------------

Anticipated Start Date:                 January 1, [****]
Anticipated Completion Date:            December 1, [****]
Cost:                                   Four million four hundred thousand
                                        ($4,400,000) dollars

MMI will screen [****] ([****])  Validated SNPs per thirty (30) days and deliver
to The Cargill Entities, after the end of each such period, the report set forth
in Part 2 of the Work Plan.

PART 3 -- ASSOCIATION STUDY -- PHASE TWO
----------------------------------------

Anticipated Start Date:                 January 1, [****]
Anticipated Completion Date:            March 1, [****]
Cost:                                   One million one hundred thousand
                                        ($1,100,000) dollars

By March 1, [****],  MMI will deliver the Associated SNP Sets and the report set
forth in Part 3 of the Work Plan.

PART 4 -- DEVELOPMENT AND VALIDATION OF DIAGNOSTIC PRODUCTS
-----------------------------------------------------------

Anticipated Start Date:                 April 1, [****]
Anticipated Completion Date:            June 1, [****]
Cost:                                   Four hundred thousand ($400,000) dollars

By May 15,  [****],  MMI will  deliver the  Diagnostic  SNP Sets for each of the
Targeted Traits and the report set forth in Part 4 of the Work Plan.

PAYMENT SCHEDULE

Upon the full  execution of this  Agreement,  The Cargill  Entities will make an
initial payment of $2,040,000  (the "Initial  Payment") to MMI.  Thereafter,  in
accordance  with  Section 3, The  Cargill  Entities  shall  remit the  following
payments,  except  for the  Initial  Payment,  to MMI  following  the  full  and
successful completion of each Part of the Work Plan, as follows:

                                       40
<PAGE>

        Part I SNP Map Validation phase          $2,260,000    $4,300,000 in
        Part 2 Association Study -- Phase One    $4,400,000    total, of which
        Part 3 Association Study -- Phase Two    $1,100,000    $2,040,000 has
        Part 4 Development and Validation of     $  400,000    already been paid
                Diagnostic Products

V.      PAYMENTS & INVOICING

        All  payments  under  this  Agreement  shall be made in U.S.  dollars by
        deposit to the credit and account of MMI as follows:

        BY MAIL TO:
        MetaMorphix, Inc.
        8510A Corridor Road
        Savage, Maryland 20763
        Attn:  Michael R.N. Thomas, Vice President and CFO

        BY WIRE TO:
        Bank of America, N.A.
        10 Light Street
        Baltimore, Maryland 21202
        [****]
        Beneficiary Name: MetaMorphix, Inc.
        Beneficiary Account Number: [****]

        Invoices should be sent to:

        Excel Corporation
        151 N. Main Street
        Wichita, Kansas 67202
        Attn:  [****]

                                       41

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]